1
|
Muhi S, Buultjens AH, Porter JL, Marshall JL, Doerflinger M, Pidot SJ, O'Brien DP, Johnson PDR, Lavender CJ, Globan M, McCarthy J, Osowicki J, Stinear TP. Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model. PLoS Negl Trop Dis 2024; 18:e0011979. [PMID: 38701090 DOI: 10.1371/journal.pntd.0011979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 04/21/2024] [Indexed: 05/05/2024] Open
Abstract
Critical scientific questions remain regarding infection with Mycobacterium ulcerans, the organism responsible for the neglected tropical disease, Buruli ulcer (BU). A controlled human infection model has the potential to accelerate our knowledge of the immunological correlates of disease, to test prophylactic interventions and novel therapeutics. Here we present microbiological evidence supporting M. ulcerans JKD8049 as a suitable human challenge strain. This non-genetically modified Australian isolate is susceptible to clinically relevant antibiotics, can be cultured in animal-free and surfactant-free media, can be enumerated for precise dosing, and has stable viability following cryopreservation. Infectious challenge of humans with JKD8049 is anticipated to imitate natural infection, as M. ulcerans JKD8049 is genetically stable following in vitro passage and produces the key virulence factor, mycolactone. Also reported are considerations for the manufacture, storage, and administration of M. ulcerans JKD8049 for controlled human infection.
Collapse
Affiliation(s)
- Stephen Muhi
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Andrew H Buultjens
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Jessica L Porter
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Julia L Marshall
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Marcel Doerflinger
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Sacha J Pidot
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Daniel P O'Brien
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
- Department of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia
| | - Paul D R Johnson
- Northeast Public Health Unit, Austin Health, Heidelberg, Victoria, Australia
| | - Caroline J Lavender
- Victorian Infectious Disease Reference Laboratory (VIDRL), Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Maria Globan
- Victorian Infectious Disease Reference Laboratory (VIDRL), Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - James McCarthy
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Joshua Osowicki
- Tropical Diseases Research Group, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia
- Infectious Diseases Unit, Department of General Medicine, Royal Children's Hospital Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Victoria, Australia
| | - Timothy P Stinear
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Victorian Infectious Disease Reference Laboratory (VIDRL), Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study. Lancet Microbe 2024:S2666-5247(24)00025-9. [PMID: 38703782 DOI: 10.1016/s2666-5247(24)00025-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 01/10/2024] [Accepted: 01/18/2024] [Indexed: 05/06/2024]
Abstract
BACKGROUND A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2, a CHIM that could be used for vaccine development will need to induce infection in those with pre-existing immunity. Our aim was to find a dose of pre-alpha SARS-CoV-2 virus that induced infection in previously infected individuals. METHODS Healthy, UK volunteers aged 18-30 years, with proven (quantitative RT-PCR or lateral flow antigen test) previous SARS-CoV-2 infection (with or without vaccination) were inoculated intranasally in a stepwise dose escalation CHIM with either 1×101, 1×102, 1×10³, 1×104, or 1×105 TCID50 SARS-CoV-2/human/GBR/484861/2020, the same virus used in the seronegative CHIM. Post-inoculation, volunteers were quarantined in functionally negative pressure rooms (Oxford, UK) for 14 days and until 12-hourly combined oropharyngeal-nasal swabs were negative for viable virus by focus-forming assay. Outpatient follow-up continued for 12 months post-enrolment, with additional visits for those who developed community-acquired SARS-CoV-2 infection. The primary objective was to identify a safe, well tolerated dose that induced infection (defined as two consecutive SARS-CoV-2 positive PCRs starting 24 h after inoculation) in 50% of seropositive volunteers. This study is registered with ClinicalTrials.gov (NCT04864548); enrolment and follow-up to 12 months post-enrolment are complete. FINDINGS Recruitment commenced on May 6, 2021, with the last volunteer enrolled into the dose escalation cohort on Nov 24, 2022. 36 volunteers were enrolled, with four to eight volunteers inoculated in each dosing group from 1×101 to 1×105 TCID50 SARS-CoV-2. All volunteers have completed quarantine, with follow-up to 12 months complete. Despite dose escalation to 1×105 TCID50, we were unable to induce sustained infection in any volunteers. Five (14%) of 36 volunteers were considered to have transient infection, based on the kinetic of their PCR-positive swabs. Transiently infected volunteers had significantly lower baseline mucosal and systemic SARS-CoV-2-specific antibody titres and significantly lower peripheral IFNγ responses against a CD8+ T-cell SARS-CoV-2 peptide pool than uninfected volunteers. 14 (39%) of 36 volunteers subsequently developed breakthrough infection with the omicron variant after discharge from quarantine. Most adverse events reported by volunteers in quarantine were mild, with fatigue (16 [44%]) and stuffy nose (16 [44%]) being the most common. There were no serious adverse events. INTERPRETATION Our study demonstrates potent protective immunity induced by homologous vaccination and homologous or heterologous previous SARS-CoV-2 infection. The community breakthrough infections seen with the omicron variant supports the use of newer variants to establish a model with sufficient rate of infection for use in vaccine and therapeutic development. FUNDING Wellcome Trust and Department for Health and Social Care.
Collapse
Affiliation(s)
- Susan Jackson
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Julia L Marshall
- Department of Paediatrics, University of Oxford, Oxford, UK; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia
| | - Andrew Mawer
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | | | - Iman Satti
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Eileen Hughes
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | | | - Stephanie Longet
- The Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Tom Tipton
- The Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Stephen Laidlaw
- The Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | - Hazel Morrison
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | - Rachel Tanner
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Alberta Ateere
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | - Meng-San Wu
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | - Judith Breuer
- Institute of Child Health, University College London, London, UK
| | - Garth Rapeport
- National Heart and Lung Institute, Imperial College London, London, UK
| | | | - Fergus Gleeson
- Oxford Radiology Research Unit, University of Oxford, Oxford, UK
| | - Andrew J Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Miles Carroll
- The Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | - Christopher Chiu
- Department of Infectious Disease, Imperial College London, London, UK
| | - Helen McShane
- Department of Paediatrics, University of Oxford, Oxford, UK.
| |
Collapse
|
3
|
Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial. Lancet Infect Dis 2024:S1473-3099(24)00143-9. [PMID: 38621405 DOI: 10.1016/s1473-3099(24)00143-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 02/16/2024] [Accepted: 02/20/2024] [Indexed: 04/17/2024]
Abstract
BACKGROUND Mycobacterium tuberculosis is the main causative agent of tuberculosis. BCG, the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis. Controlled human infection models are useful tools for vaccine development. We aimed to determine a safe dose of aerosol-inhaled live-attenuated Mycobacterium bovis BCG as a surrogate for M tuberculosis infection, then compare the safety and tolerability of infection models established using aerosol-inhaled and intradermally administered BCG. METHODS This phase 1 controlled human infection trial was conducted at two clinical research facilities in the UK. Healthy, immunocompetent adults aged 18-50 years, who were both M tuberculosis-naive and BCG-naive and had no history of asthma or other respiratory diseases, were eligible for the trial. Participants were initially enrolled into group 1 (receiving the BCG Danish strain); the trial was subsequently paused because of a worldwide shortage of BCG Danish and, after protocol amendment, was restarted using the BCG Bulgaria strain (group 2). After a dose-escalation study, during which participants were sequentially allocated to receive either 1 × 103, 1 × 104, 1 × 105, 1 × 106, or 1 × 107 colony-forming units (CFU) of aerosol BCG, the maximum tolerated dose was selected for the randomised controlled trial. Participants in this trial were randomly assigned (9:12), by variable block randomisation and using sequentially numbered sealed envelopes, to receive aerosol BCG (1 × 107 CFU) and intradermal saline or intradermal BCG (1 × 106 CFU) and aerosol saline. Participants were masked to treatment allocation until day 14. The primary outcome was to compare the safety of a controlled human infection model based on aerosol-inhaled BCG versus one based on intradermally administered BCG, and the secondary outcome was to evaluate BCG recovery in the airways of participants who received aerosol BCG or skin biopsies of participants who received intradermal BCG. BCG was detected by culture and by PCR. The trial is registered at ClinicalTrials.gov, NCT02709278, and is complete. FINDINGS Participants were assessed for eligibility between April 7, 2016, and Sept 29, 2018. For group 1, 15 participants were screened, of whom 13 were enrolled and ten completed the study; for group 2, 60 were screened and 33 enrolled, all of whom completed the study. Doses up to 1 × 107 CFU aerosol-inhaled BCG were sufficiently well tolerated. No significant difference was observed in the frequency of adverse events between aerosol and intradermal groups (median percentage of solicited adverse events per participant, post-aerosol vs post-intradermal BCG: systemic 7% [IQR 2-11] vs 4% [1-13], p=0·62; respiratory 7% [1-19] vs 4% [1-9], p=0·56). More severe systemic adverse events occurred in the 2 weeks after aerosol BCG (15 [12%] of 122 reported systemic adverse events) than after intradermal BCG (one [1%] of 94; difference 11% [95% CI 5-17]; p=0·0013), but no difference was observed in the severity of respiratory adverse events (two [1%] of 144 vs zero [0%] of 97; 1% [-1 to 3]; p=0·52). All adverse events after aerosol BCG resolved spontaneously. One serious adverse event was reported-a participant in group 2 was admitted to hospital to receive analgesia for a pre-existing ovarian cyst, which was deemed unrelated to BCG infection. On day 14, BCG was cultured from bronchoalveolar lavage samples after aerosol infection and from skin biopsy samples after intradermal infection. INTERPRETATION This first-in-human aerosol BCG controlled human infection model was sufficiently well tolerated. Further work will evaluate the utility of this model in assessing vaccine efficacy and identifying potential correlates of protection. FUNDING Bill & Melinda Gates Foundation, Wellcome Trust, National Institute for Health Research Oxford Biomedical Research Centre, Thames Valley Clinical Research Network, and TBVAC2020.
Collapse
Affiliation(s)
- Iman Satti
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | | | | | - Rachel Tanner
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | - Morven Wilkie
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | - Michael Riste
- The Jenner Institute, University of Oxford, Oxford, UK
| | - Daniel Wright
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | - Nicola Williams
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | | | | | | | - Daniel Jenkin
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | - Linnea Rask
- The Jenner Institute, University of Oxford, Oxford, UK
| | | | | | - Alison Lawrie
- The Jenner Institute, University of Oxford, Oxford, UK
| | - Paul Moss
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Timothy Hinks
- Oxford Centre for Respiratory Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Henry Bettinson
- Oxford Centre for Respiratory Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Helen McShane
- The Jenner Institute, University of Oxford, Oxford, UK.
| |
Collapse
|
4
|
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis 2024; 24:285-296. [PMID: 38012890 DOI: 10.1016/s1473-3099(23)00501-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Revised: 07/21/2023] [Accepted: 07/31/2023] [Indexed: 11/29/2023]
Abstract
BACKGROUND BCG confers reduced, variable protection against pulmonary tuberculosis. A more effective vaccine is needed. We evaluated the safety and immunogenicity of candidate regimen ChAdOx1 85A-MVA85A compared with BCG revaccination among Ugandan adolescents. METHODS After ChAdOx1 85A dose escalation and age de-escalation, we did a randomised open-label phase 2a trial among healthy adolescents aged 12-17 years, who were BCG vaccinated at birth, without evident tuberculosis exposure, in Entebbe, Uganda. Participants were randomly assigned (1:1) using a block size of 6, to ChAdOx1 85A followed by MVA85A (on day 56) or BCG (Moscow strain). Laboratory staff were masked to group assignment. Primary outcomes were solicited and unsolicited adverse events (AEs) up to day 28 and serious adverse events (SAEs) throughout the trial; and IFN-γ ELISpot response to antigen 85A (day 63 [geometric mean] and days 0-224 [area under the curve; AUC). FINDINGS Six adults (group 1, n=3; group 2, n=3) and six adolescents (group 3, n=3; group 4, n=3) were enrolled in the ChAdOx1 85A-only dose-escalation and age de-escalation studies (July to August, 2019). In the phase 2a trial, 60 adolescents were randomly assigned to ChAdOx1 85A-MVA85A (group 5, n=30) or BCG (group 6, n=30; December, 2019, to October, 2020). All 60 participants from groups 5 and 6 were included in the safety analysis, with 28 of 30 from group 5 (ChAdOx1 85A-MVA85A) and 29 of 30 from group 6 (BCG revaccination) analysed for immunogenicity outcomes. In the randomised trial, 60 AEs were reported among 23 (77%) of 30 participants following ChAdOx1 85A-MVA85A, 31 were systemic, with one severe event that occurred after the MVA85A boost that was rapidly self-limiting. All 30 participants in the BCG revaccination group reported at least one mild to moderate solicited AE; most were local reactions. There were no SAEs in either group. Ag85A-specific IFN-γ ELISpot responses peaked on day 63 in the ChAdOx1 85A-MVA85A group and were higher in the ChAdOx1 85A-MVA85A group compared with the BCG revaccination group (geometric mean ratio 30·59 [95% CI 17·46-53·59], p<0·0001, day 63; AUC mean difference 57 091 [95% CI 40 524-73 658], p<0·0001, days 0-224). INTERPRETATION The ChAdOx1 85A-MVA85A regimen was safe and induced stronger Ag85A-specific responses than BCG revaccination. Our findings support further development of booster tuberculosis vaccines. FUNDING UK Research and Innovations and Medical Research Council. TRANSLATIONS For the Swahili and Luganda translations of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Anne Wajja
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Global Health, Amsterdam University Medical Centers, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
| | - Beatrice Nassanga
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK; Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
| | | | - Joel Serubanja
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | | | - Helen Akurut
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | - Gloria Oduru
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | | | | | - Hazel Morrison
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
| | - Hannah Scott
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Rebecca Powell Doherty
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Julia L Marshall
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Ingrid Cabrera Puig
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Stephen Cose
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
| | - Pontiano Kaleebu
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
| | - Emily L Webb
- Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
| | - Iman Satti
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Helen McShane
- The Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
| | - Alison M Elliott
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
| |
Collapse
|
5
|
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control. Lancet Infect Dis 2024; 24:e78-e79. [PMID: 38184003 DOI: 10.1016/s1473-3099(23)00758-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 12/04/2023] [Indexed: 01/08/2024]
Affiliation(s)
- Anne Wajja
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
| | - Beatrice Nassanga
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; The Jenner Institute, Old Road Campus Research Building, Oxford, UK; Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
| | | | - Joel Serubanja
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | | | - Helen Akurut
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | - Gloria Oduru
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda
| | | | | | - Hazel Morrison
- The Jenner Institute, Old Road Campus Research Building, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, UK
| | - Hannah Scott
- The Jenner Institute, Old Road Campus Research Building, Oxford, UK
| | | | - Julia L Marshall
- The Jenner Institute, Old Road Campus Research Building, Oxford, UK
| | | | - Stephen Cose
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
| | - Pontiano Kaleebu
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
| | - Emily L Webb
- Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | - Iman Satti
- The Jenner Institute, Old Road Campus Research Building, Oxford, UK
| | - Helen McShane
- The Jenner Institute, Old Road Campus Research Building, Oxford, UK; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, UK
| | - Alison M Elliott
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
| |
Collapse
|
6
|
Muhi S, Osowicki J, O'Brien D, Johnson PDR, Pidot S, Doerflinger M, Marshall JL, Pellegrini M, McCarthy J, Stinear TP. A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain. PLoS Negl Trop Dis 2023; 17:e0011394. [PMID: 37384606 DOI: 10.1371/journal.pntd.0011394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/01/2023] Open
Abstract
Critical knowledge gaps regarding infection with Mycobacterium ulcerans, the cause of Buruli ulcer (BU), have impeded development of new therapeutic approaches and vaccines for prevention of this neglected tropical disease. Here, we review the current understanding of host-pathogen interactions and correlates of immune protection to explore the case for establishing a controlled human infection model of M. ulcerans infection. We also summarise the overarching safety considerations and present a rationale for selecting a suitable challenge strain.
Collapse
Affiliation(s)
- Stephen Muhi
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Joshua Osowicki
- Tropical Diseases Research Group, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia
- Infectious Diseases Unit, Department of General Medicine, Royal Children's Hospital Melbourne, Victoria, Australia
- Department of Paediatrics, University of Melbourne, Victoria, Australia
| | - Daniel O'Brien
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
- Barwon Health, Geelong, Victoria, Australia
| | - Paul D R Johnson
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Austin Health, Heidelberg, Victoria, Australia
| | - Sacha Pidot
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Marcel Doerflinger
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Julia L Marshall
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| | - Marc Pellegrini
- Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - James McCarthy
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Timothy P Stinear
- Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
7
|
To C, Krause E, Rozo E, Wu H, Gruen D, Wechsler RH, Eifler TF, Rykoff ES, Costanzi M, Becker MR, Bernstein GM, Blazek J, Bocquet S, Bridle SL, Cawthon R, Choi A, Crocce M, Davis C, DeRose J, Drlica-Wagner A, Elvin-Poole J, Fang X, Farahi A, Friedrich O, Gatti M, Gaztanaga E, Giannantonio T, Hartley WG, Hoyle B, Jarvis M, MacCrann N, McClintock T, Miranda V, Pereira MES, Park Y, Porredon A, Prat J, Rau MM, Ross AJ, Samuroff S, Sánchez C, Sevilla-Noarbe I, Sheldon E, Troxel MA, Varga TN, Vielzeuf P, Zhang Y, Zuntz J, Abbott TMC, Aguena M, Amon A, Annis J, Avila S, Bertin E, Bhargava S, Brooks D, Burke DL, Carnero Rosell A, Carrasco Kind M, Carretero J, Chang C, Conselice C, da Costa LN, Davis TM, Desai S, Diehl HT, Dietrich JP, Everett S, Evrard AE, Ferrero I, Flaugher B, Fosalba P, Frieman J, García-Bellido J, Gruendl RA, Gutierrez G, Hinton SR, Hollowood DL, Honscheid K, Huterer D, James DJ, Jeltema T, Kron R, Kuehn K, Kuropatkin N, Lima M, Maia MAG, Marshall JL, Menanteau F, Miquel R, Morgan R, Muir J, Myles J, Palmese A, Paz-Chinchón F, Plazas AA, Romer AK, Roodman A, Sanchez E, Santiago B, Scarpine V, Serrano S, Smith M, Suchyta E, Swanson MEC, Tarle G, Thomas D, Tucker DL, Weller J, Wester W, Wilkinson RD. Dark Energy Survey Year 1 Results: Cosmological Constraints from Cluster Abundances, Weak Lensing, and Galaxy Correlations. Phys Rev Lett 2021; 126:141301. [PMID: 33891448 DOI: 10.1103/physrevlett.126.141301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 01/07/2021] [Accepted: 02/23/2021] [Indexed: 06/12/2023]
Abstract
We present the first joint analysis of cluster abundances and auto or cross-correlations of three cosmic tracer fields: galaxy density, weak gravitational lensing shear, and cluster density split by optical richness. From a joint analysis (4×2pt+N) of cluster abundances, three cluster cross-correlations, and the auto correlations of the galaxy density measured from the first year data of the Dark Energy Survey, we obtain Ω_{m}=0.305_{-0.038}^{+0.055} and σ_{8}=0.783_{-0.054}^{+0.064}. This result is consistent with constraints from the DES-Y1 galaxy clustering and weak lensing two-point correlation functions for the flat νΛCDM model. Consequently, we combine cluster abundances and all two-point correlations from across all three cosmic tracer fields (6×2pt+N) and find improved constraints on cosmological parameters as well as on the cluster observable-mass scaling relation. This analysis is an important advance in both optical cluster cosmology and multiprobe analyses of upcoming wide imaging surveys.
Collapse
Affiliation(s)
- C To
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - E Krause
- Department of Astronomy/Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - E Rozo
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - H Wu
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, Boise State University, Boise, Idaho 83725, USA
| | - D Gruen
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - R H Wechsler
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T F Eifler
- Department of Astronomy/Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
| | - E S Rykoff
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Costanzi
- INAF-Osservatorio Astronomico di Trieste, via G. B. Tiepolo 11, I-34143 Trieste, Italy
- Institute for Fundamental Physics of the Universe, Via Beirut 2, 34014 Trieste, Italy
| | - M R Becker
- Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois 60439, USA
| | - G M Bernstein
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - J Blazek
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Institute of Physics, Laboratory of Astrophysics, École Polytechnique Fédérale de Lausanne (EPFL), Observatoire de Sauverny, 1290 Versoix, Switzerland
| | - S Bocquet
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, 81679 Munich, Germany
| | - S L Bridle
- Jodrell Bank Center for Astrophysics, School of Physics and Astronomy, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - R Cawthon
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue Madison, Wisconsin 53706-1390
| | - A Choi
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - M Crocce
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - C Davis
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - J DeRose
- Department of Astronomy, University of California, Berkeley, 501 Campbell Hall, Berkeley, California 94720, USA
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - A Drlica-Wagner
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Elvin-Poole
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - X Fang
- Department of Astronomy/Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
| | - A Farahi
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - O Friedrich
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
| | - M Gatti
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - E Gaztanaga
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - T Giannantonio
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
| | - W G Hartley
- Département de Physique Théorique and Center for Astroparticle Physics, Université de Genève, 24 quai Ernest Ansermet, CH-1211 Geneva, Switzerland
- Department of Physics & Astronomy, University College London, Gower Street, London, WC1E 6BT, United Kingdom
- Department of Physics, ETH Zurich, Wolfgang-Pauli-Strasse 16, CH-8093 Zurich, Switzerland
| | - B Hoyle
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, 81679 Munich, Germany
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
| | - M Jarvis
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - N MacCrann
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - T McClintock
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - V Miranda
- Department of Astronomy/Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
| | - M E S Pereira
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - Y Park
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - A Porredon
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - J Prat
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
| | - M M Rau
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - A J Ross
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - S Samuroff
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - C Sánchez
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - I Sevilla-Noarbe
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - E Sheldon
- Brookhaven National Laboratory, Bldg 510, Upton, New York 11973, USA
| | - M A Troxel
- Department of Physics, Duke University Durham, North Carolina 27708, USA
| | - T N Varga
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
| | - P Vielzeuf
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - Y Zhang
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J Zuntz
- Institute for Astronomy, University of Edinburgh, Edinburgh EH9 3HJ, United Kingdom
| | - T M C Abbott
- Cerro Tololo Inter-American Observatory, NSF's National Optical-Infrared Astronomy Research Laboratory, Casilla 603, La Serena, Chile
| | - M Aguena
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP, 05314-970, Brazil
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - A Amon
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - J Annis
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - S Avila
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - E Bertin
- CNRS, UMR 7095, Institut d'Astrophysique de Paris, F-75014, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, UMR 7095, Institut d'Astrophysique de Paris, F-75014, Paris, France
| | - S Bhargava
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton, BN1 9QH, United Kingdom
| | - D Brooks
- Department of Physics & Astronomy, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - D L Burke
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Carnero Rosell
- Instituto de Astrofisica de Canarias, E-38205 La Laguna, Tenerife, Spain
- Universidad de La Laguna, Dpto. Astrofsica, E-38206 La Laguna, Tenerife, Spain
| | - M Carrasco Kind
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - J Carretero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - C Chang
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C Conselice
- Jodrell Bank Center for Astrophysics, School of Physics and Astronomy, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
- University of Nottingham, School of Physics and Astronomy, Nottingham NG7 2RD, United Kingdom
| | - L N da Costa
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - T M Davis
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - S Desai
- Department of Physics, IIT Hyderabad, Kandi, Telangana 502285, India
| | - H T Diehl
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J P Dietrich
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, 81679 Munich, Germany
| | - S Everett
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - A E Evrard
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - I Ferrero
- Institute of Theoretical Astrophysics, University of Oslo. P.O. Box 1029 Blindern, NO-0315 Oslo, Norway
| | - B Flaugher
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - P Fosalba
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - J Frieman
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J García-Bellido
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - R A Gruendl
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - G Gutierrez
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - S R Hinton
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - D L Hollowood
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - K Honscheid
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - D Huterer
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D J James
- Center for Astrophysics | Harvard & Smithsonian, 60 Garden Street, Cambridge, Massachusetts 02138, USA
| | - T Jeltema
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - R Kron
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - K Kuehn
- Australian Astronomical Optics, Macquarie University, North Ryde, New South Wales 2113, Australia
- Lowell Observatory, 1400 Mars Hill Rd, Flagstaff, Arizona 86001, USA
| | - N Kuropatkin
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - M Lima
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP, 05314-970, Brazil
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - M A G Maia
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - F Menanteau
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - R Miquel
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
- Institució Catalana de Recerca i Estudis Avanćats, E-08010 Barcelona, Spain
| | - R Morgan
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue Madison, Wisconsin 53706-1390
| | - J Muir
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - J Myles
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - A Palmese
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Paz-Chinchón
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - A A Plazas
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - A K Romer
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton, BN1 9QH, United Kingdom
| | - A Roodman
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - E Sanchez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - B Santiago
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Instituto de Física, UFRGS, Caixa Postal 15051, Porto Alegre, RS-91501-970, Brazil
| | - V Scarpine
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - S Serrano
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - M Smith
- School of Physics and Astronomy, University of Southampton, Southampton, SO17 1BJ, United Kingdom
| | - E Suchyta
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - M E C Swanson
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - G Tarle
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D Thomas
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth, PO1 3FX, United Kingdom
| | - D L Tucker
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J Weller
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
| | - W Wester
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - R D Wilkinson
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton, BN1 9QH, United Kingdom
| |
Collapse
|
8
|
Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol 2021; 32:906-916. [PMID: 33798656 DOI: 10.1016/j.annonc.2021.03.203] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Revised: 03/21/2021] [Accepted: 03/28/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The impact of molecular alterations on programmed death-ligand 1 (PD-L1) combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features of tumors with different CPSs in GEAs. PATIENTS AND METHODS Genomic alterations of 2518 GEAs were compared in three groups (PD-L1 CPS ≥ 10, high; CPS = 1-9, intermediate; CPS < 1, low) using next-generation sequencing. We assessed the impact of gene mutations on the efficacy of immune checkpoint inhibitors (ICIs) and tumor immune environment based on the Memorial Sloan Kettering Cancer Center and The Cancer Genome Atlas databases. RESULTS High, intermediate, and low CPSs were seen in 18%, 54% and 28% of GEAs, respectively. PD-L1 positivity was less prevalent in women and in tissues derived from metastatic sites. PD-L1 CPS was positively associated with mismatch repair deficiency/microsatellite instability-high, but independent of tumor mutation burden distribution. Tumors with mutations in KRAS, TP53, and RAS-mitogen-activated protein kinase (MAPK) pathway were associated with higher PD-L1 CPSs in the mismatch repair proficiency and microsatellite stability (pMMR&MSS) subgroup. Patients with RAS-MAPK pathway alterations had longer overall survival (OS) from ICIs compared to wildtype (WT) patients [27 versus 13 months, hazard ratio (HR) = 0.36, 95% confidence interval (CI): 0.19-0.7, P = 0.016] and a similar trend was observed in the MSS subgroup (P = 0.11). In contrast, patients with TP53 mutations had worse OS from ICIs compared to TP53-WT patients in the MSS subgroup (5 versus 21 months, HR = 2.39, 95% CI: 1.24-4.61, P = 0.016). CONCLUSIONS This is the largest study to investigate the distinct genomic landscapes of GEAs with different PD-L1 CPSs. Our data may provide novel insights for patient selection using mutations in TP53 and RAS-MAPK pathway and for the development of rational combination immunotherapies in GEAs.
Collapse
Affiliation(s)
- J Y Wang
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Xiu
- Caris Life Sciences, Phoenix, USA
| | - Y Baca
- Caris Life Sciences, Phoenix, USA
| | - H Arai
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - F Battaglin
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - N Kawanishi
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - S Soni
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - W Zhang
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Millstein
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - A F Shields
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, USA
| | - A Grothey
- GI Cancer Research, West Cancer Center and Research Institute, Germantown, USA
| | - B A Weinberg
- Division of Hematology and Oncology, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
| | - J L Marshall
- Division of Hematology and Oncology, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
| | - E Lou
- Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, USA
| | - M Khushman
- Department of Interdisciplinary Clinical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, USA
| | - D P S Sohal
- Division of Hematology/Oncology, University of Cincinnati, Cincinnati, USA
| | - M J Hall
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | | | | | - L Shen
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - W M Korn
- Caris Life Sciences, Phoenix, USA
| | - H J Lenz
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA.
| |
Collapse
|
9
|
Nadler EO, Drlica-Wagner A, Bechtol K, Mau S, Wechsler RH, Gluscevic V, Boddy K, Pace AB, Li TS, McNanna M, Riley AH, García-Bellido J, Mao YY, Green G, Burke DL, Peter A, Jain B, Abbott TMC, Aguena M, Allam S, Annis J, Avila S, Brooks D, Carrasco Kind M, Carretero J, Costanzi M, da Costa LN, De Vicente J, Desai S, Diehl HT, Doel P, Everett S, Evrard AE, Flaugher B, Frieman J, Gerdes DW, Gruen D, Gruendl RA, Gschwend J, Gutierrez G, Hinton SR, Honscheid K, Huterer D, James DJ, Krause E, Kuehn K, Kuropatkin N, Lahav O, Maia MAG, Marshall JL, Menanteau F, Miquel R, Palmese A, Paz-Chinchón F, Plazas AA, Romer AK, Sanchez E, Scarpine V, Serrano S, Sevilla-Noarbe I, Smith M, Soares-Santos M, Suchyta E, Swanson MEC, Tarle G, Tucker DL, Walker AR, Wester W. Constraints on Dark Matter Properties from Observations of Milky Way Satellite Galaxies. Phys Rev Lett 2021; 126:091101. [PMID: 33750144 DOI: 10.1103/physrevlett.126.091101] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 12/12/2020] [Accepted: 01/27/2021] [Indexed: 06/12/2023]
Abstract
We perform a comprehensive study of Milky Way (MW) satellite galaxies to constrain the fundamental properties of dark matter (DM). This analysis fully incorporates inhomogeneities in the spatial distribution and detectability of MW satellites and marginalizes over uncertainties in the mapping between galaxies and DM halos, the properties of the MW system, and the disruption of subhalos by the MW disk. Our results are consistent with the cold, collisionless DM paradigm and yield the strongest cosmological constraints to date on particle models of warm, interacting, and fuzzy dark matter. At 95% confidence, we report limits on (i) the mass of thermal relic warm DM, m_{WDM}>6.5 keV (free-streaming length, λ_{fs}≲10h^{-1} kpc), (ii) the velocity-independent DM-proton scattering cross section, σ_{0}<8.8×10^{-29} cm^{2} for a 100 MeV DM particle mass [DM-proton coupling, c_{p}≲(0.3 GeV)^{-2}], and (iii) the mass of fuzzy DM, m_{ϕ}>2.9×10^{-21} eV (de Broglie wavelength, λ_{dB}≲0.5 kpc). These constraints are complementary to other observational and laboratory constraints on DM properties.
Collapse
Affiliation(s)
- E O Nadler
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics and Cosmology, P.O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Drlica-Wagner
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
| | - K Bechtol
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue, Madison, Wisconsin 53706-1390, USA
| | - S Mau
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics and Cosmology, P.O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - R H Wechsler
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics and Cosmology, P.O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - V Gluscevic
- University of Southern California, Department of Physics and Astronomy, 825 Bloom Walk ACB 439, Los Angeles, California 90089-0484, USA
| | - K Boddy
- Theory Group, Department of Physics, The University of Texas at Austin, Austin, Texas 78712, USA
| | - A B Pace
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - T S Li
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
- Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, California 91101, USA
| | - M McNanna
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue, Madison, Wisconsin 53706-1390, USA
| | - A H Riley
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - J García-Bellido
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - Y-Y Mao
- Department of Physics and Astronomy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
| | - G Green
- Max Planck Institute for Astronomy, Königstuhl 17 D-69117, Heidelberg, Germany
| | - D L Burke
- Kavli Institute for Particle Astrophysics and Cosmology, P.O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Peter
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Astronomy, The Ohio State University, Columbus, Ohio 43210, USA
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - B Jain
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - T M C Abbott
- Cerro Tololo Inter-American Observatory, NSF's National Optical-Infrared Astronomy Research Laboratory, Casilla 603, La Serena, Chile
| | - M Aguena
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP, 05314-970, Brazil
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - S Allam
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - J Annis
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - S Avila
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - D Brooks
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - M Carrasco Kind
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - J Carretero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona), Spain
| | - M Costanzi
- INAF-Osservatorio Astronomico di Trieste, via G.B. Tiepolo 11, I-34143 Trieste, Italy
- Institute for Fundamental Physics of the Universe, Via Beirut 2, 34014 Trieste, Italy
| | - L N da Costa
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J De Vicente
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - S Desai
- Department of Physics, IIT Hyderabad, Kandi, Telangana 502285, India
| | - H T Diehl
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - P Doel
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - S Everett
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - A E Evrard
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - B Flaugher
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - J Frieman
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - D W Gerdes
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D Gruen
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics and Cosmology, P.O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - R A Gruendl
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - J Gschwend
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - G Gutierrez
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - S R Hinton
- School of Mathematics and Physics, University of Queensland, Brisbane, Queensland 4072, Australia
| | - K Honscheid
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - D Huterer
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D J James
- Center for Astrophysics, Harvard and Smithsonian, 60 Garden Street, Cambridge, Massachusetts 02138, USA
| | - E Krause
- Department of Astronomy/Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
| | - K Kuehn
- Australian Astronomical Optics, Macquarie University, North Ryde, New South Wales 2113, Australia
- Lowell Observatory, 1400 Mars Hill Road, Flagstaff, Arizona 86001, USA
| | - N Kuropatkin
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - O Lahav
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - M A G Maia
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - F Menanteau
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - R Miquel
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona), Spain
- Institució Catalana de Recerca i Estudis Avançats, E-08010 Barcelona, Spain
| | - A Palmese
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Paz-Chinchón
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
| | - A A Plazas
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - A K Romer
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton, BN1 9QH, United Kingdom
| | - E Sanchez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - V Scarpine
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - S Serrano
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - I Sevilla-Noarbe
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M Smith
- School of Physics and Astronomy, University of Southampton, Southampton, SO17 1BJ, United Kingdom
| | - M Soares-Santos
- Brandeis University, Physics Department, 415 South Street, Waltham, Massachusetts 02453, USA
| | - E Suchyta
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M E C Swanson
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - G Tarle
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D L Tucker
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| | - A R Walker
- Cerro Tololo Inter-American Observatory, NSF's National Optical-Infrared Astronomy Research Laboratory, Casilla 603, La Serena, Chile
| | - W Wester
- Fermi National Accelerator Laboratory, P.O. Box 500, Batavia, Illinois 60510, USA
| |
Collapse
|
10
|
Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol 2020; 31:480-486. [PMID: 32085892 PMCID: PMC10688027 DOI: 10.1016/j.annonc.2019.12.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 12/16/2019] [Accepted: 12/17/2019] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Since 2004, adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX or FLOX) have been the standard of care for patients with resected colon cancer. Herein we examine the change of outcomes over a 10-year period in patients with stage III colon cancer who received this regimen. PATIENTS AND METHODS Individual patient data from the ACCENT database was used to compare the outcomes in older (1998-2003) and newer (2004-2009) treatment eras for patients with stage III colon cancer who received adjuvant FOLFOX or FLOX. The outcomes were compared between the two groups by the multivariate Cox proportional-hazards model adjusting for age, sex, performance score, T stage, N stage, tumor sidedness, and histological grade. RESULTS A total of 6501 patients with stage III colon cancer who received adjuvant FOLFOX or FLOX in six randomized trials were included in the analysis. Patients enrolled in the new era group experienced statistically significant improvement in time to recurrence [3-year rate, 76.1% versus 73.0%; adjusted hazard ratio (HRadj) = 0.83 (95% CI, 0.74-0.92), P = 0.0008], disease-free survival (DFS) [3-year rate, 74.7% versus 72.3%; HRadj = 0.88 (0.79-0.98), P = 0.024], survival after recurrence (SAR) [median time, 27.0 versus 17.7 months; HRadj = 0.65 (0.57-0.74), P < 0.0001], and overall survival (OS) [5-year rate, 80.9% versus 75.7%; HRadj = 0.78 (0.69-0.88), P < 0.0001]. The improved outcomes remained in patients diagnosed at 45 years of age or older, low-risk patients (T1-3 and N1), left colon, mismatch repair proficient (pMMR), BRAF, and KRAS wild-type tumors. CONCLUSION Improved outcomes were observed in patients with stage III colon cancer enrolled in clinical trials who received adjuvant FOLFOX/FLOX therapy in 2004 or later compared with patients in the older era. Prolonged SAR calls for revalidation of 3-year DFS as the surrogate endpoint of OS in adjuvant clinical trials and reevaluation of optimal follow-up of OS to confirm the trial findings based on the DFS endpoints. CLINICAL TRIALS NUMBERS NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918.
Collapse
Affiliation(s)
- M E Salem
- Levine Cancer Institute, Carolinas HealthCare System, Charlotte, USA
| | - J Yin
- Department of Health Science Research, Mayo Clinic, Rochester, USA
| | - R M Goldberg
- West Virginia University Cancer Institute, Morgantown, USA
| | - L D Pederson
- Department of Health Science Research, Mayo Clinic, Rochester, USA
| | - N Wolmark
- National Surgical Adjuvant Breast and Bowel Project (NSABP/NRG Oncology), Pittsburgh, USA
| | - S R Alberts
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - J Taieb
- Department of Gastroenterology and GI Oncology, Georges Pompidou European Hospital, Paris Descartes University, Paris, France
| | - J L Marshall
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
| | - S Lonardi
- Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy
| | - T Yoshino
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - R S Kerr
- Department of Oncology, University of Oxford, Oxford, UK
| | - G Yothers
- Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, USA
| | - A Grothey
- West Cancer Center and Research Institute, Germantown, USA
| | - T Andre
- Sorbonne University and Department of Medical Oncology, Hôspital St Antoine, Paris, France
| | - A De Gramont
- Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France
| | - Q Shi
- Department of Health Science Research, Mayo Clinic, Rochester, USA.
| |
Collapse
|
11
|
Ammazzalorso S, Gruen D, Regis M, Camera S, Ando S, Fornengo N, Bechtol K, Bridle SL, Choi A, Eifler TF, Gatti M, MacCrann N, Omori Y, Samuroff S, Sheldon E, Troxel MA, Zuntz J, Carrasco Kind M, Annis J, Avila S, Bertin E, Brooks D, Burke DL, Carnero Rosell A, Carretero J, Castander FJ, Costanzi M, da Costa LN, De Vicente J, Desai S, Diehl HT, Dietrich JP, Doel P, Everett S, Flaugher B, Fosalba P, García-Bellido J, Gaztanaga E, Gerdes DW, Giannantonio T, Goldstein DA, Gruendl RA, Gutierrez G, Hollowood DL, Honscheid K, James DJ, Jarvis M, Jeltema T, Kent S, Kuropatkin N, Lahav O, Li TS, Lima M, Maia MAG, Marshall JL, Melchior P, Menanteau F, Miquel R, Ogando RLC, Palmese A, Plazas AA, Romer AK, Roodman A, Rykoff ES, Sánchez C, Sanchez E, Scarpine V, Serrano S, Sevilla-Noarbe I, Smith M, Soares-Santos M, Sobreira F, Suchyta E, Swanson MEC, Tarle G, Thomas D, Vikram V, Zhang Y. Detection of Cross-Correlation between Gravitational Lensing and γ Rays. Phys Rev Lett 2020; 124:101102. [PMID: 32216401 DOI: 10.1103/physrevlett.124.101102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 12/14/2019] [Accepted: 01/13/2020] [Indexed: 06/10/2023]
Abstract
In recent years, many γ-ray sources have been identified, yet the unresolved component hosts valuable information on the faintest emission. In order to extract it, a cross-correlation with gravitational tracers of matter in the Universe has been shown to be a promising tool. We report here the first identification of a cross-correlation signal between γ rays and the distribution of mass in the Universe probed by weak gravitational lensing. We use data from the Dark Energy Survey Y1 weak lensing data and the Fermi Large Area Telescope 9-yr γ-ray data, obtaining a signal-to-noise ratio of 5.3. The signal is mostly localized at small angular scales and high γ-ray energies, with a hint of correlation at extended separation. Blazar emission is likely the origin of the small-scale effect. We investigate implications of the large-scale component in terms of astrophysical sources and particle dark matter emission.
Collapse
Affiliation(s)
- S Ammazzalorso
- Dipartimento di Fisica, Università degli Studi di Torino, via Pietro Giuria 1, 10125 Torino, Italy
- INFN-Istituto Nazionale di Fisica Nucleare, Sezione di Torino, via Pietro Giuria 1, 10125 Torino, Italy
| | - D Gruen
- Kavli Institute for Particle Astrophysics and Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Regis
- Dipartimento di Fisica, Università degli Studi di Torino, via Pietro Giuria 1, 10125 Torino, Italy
- INFN-Istituto Nazionale di Fisica Nucleare, Sezione di Torino, via Pietro Giuria 1, 10125 Torino, Italy
| | - S Camera
- Dipartimento di Fisica, Università degli Studi di Torino, via Pietro Giuria 1, 10125 Torino, Italy
- INFN-Istituto Nazionale di Fisica Nucleare, Sezione di Torino, via Pietro Giuria 1, 10125 Torino, Italy
- INAF-Istituto Nazionale di Astrofisica, Osservatorio Astrofisico di Torino, strada Osservatorio 20, 10025 Pino Torinese, Italy
- Department of Physics and Astronomy, University of the Western Cape, Cape Town 7535, South Africa
| | - S Ando
- GRAPPA Institute, University of Amsterdam, 1098 XH Amsterdam, The Netherlands
- Kavli Institute for the Physics and Mathematics of the Universe, University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - N Fornengo
- Dipartimento di Fisica, Università degli Studi di Torino, via Pietro Giuria 1, 10125 Torino, Italy
- INFN-Istituto Nazionale di Fisica Nucleare, Sezione di Torino, via Pietro Giuria 1, 10125 Torino, Italy
| | - K Bechtol
- LSST, 933 North Cherry Avenue, Tucson, Arizona 85721, USA
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue Madison, Wisconsin 53706-1390, USA
| | - S L Bridle
- Jodrell Bank Center for Astrophysics, School of Physics and Astronomy, University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom
| | - A Choi
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - T F Eifler
- Department of Astronomy and Steward Observatory, University of Arizona, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
- Jet Propulsion Laboratory, California Institute of Technology, 4800 Oak Grove Drive, Pasadena, California 91109, USA
| | - M Gatti
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - N MacCrann
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - Y Omori
- Kavli Institute for Particle Astrophysics and Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - S Samuroff
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - E Sheldon
- Brookhaven National Laboratory, Building 510, Upton, New York 11973, USA
| | - M A Troxel
- Department of Physics, Duke University Durham, North Carolina 27708, USA
| | - J Zuntz
- Institute for Astronomy, University of Edinburgh, Edinburgh EH9 3HJ, United Kingdom
| | - M Carrasco Kind
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - J Annis
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - S Avila
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - E Bertin
- CNRS, UMR 7095, Institut d'Astrophysique de Paris, F-75014 Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, UMR 7095, Institut d'Astrophysique de Paris, F-75014 Paris, France
| | - D Brooks
- Department of Physics and Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - D L Burke
- Kavli Institute for Particle Astrophysics and Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Carnero Rosell
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J Carretero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - F J Castander
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - M Costanzi
- INAF-Osservatorio Astronomico di Trieste, via Giambattista Tiepolo 11, 34143 Trieste, Italy
- IFPU-Institute for Fundamental Physics of the Universe, Via Beirut 2, 34014 Trieste, Italy
| | - L N da Costa
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J De Vicente
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - S Desai
- Department of Physics, IIT Hyderabad, Kandi, Telangana 502285, India
| | - H T Diehl
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J P Dietrich
- Excellence Cluster Origins, Boltzmannstrasse 2, 85748 Garching, Germany
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstrasse 1, 81679 Munich, Germany
| | - P Doel
- Department of Physics and Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - S Everett
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - B Flaugher
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - P Fosalba
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - J García-Bellido
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - E Gaztanaga
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - D W Gerdes
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - T Giannantonio
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
| | - D A Goldstein
- California Institute of Technology, 1200 East California Boulevard, MC 249-17, Pasadena, California 91125, USA
| | - R A Gruendl
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - G Gutierrez
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - D L Hollowood
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - K Honscheid
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - D J James
- Center for Astrophysics, Harvard-Smithsonian, 60 Garden Street, Cambridge, Massachusetts 02138, USA
| | - M Jarvis
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - T Jeltema
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - S Kent
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - N Kuropatkin
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - O Lahav
- Department of Physics and Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - T S Li
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Lima
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP, 05314-970, Brazil
| | - M A G Maia
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - P Melchior
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - F Menanteau
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 West Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - R Miquel
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra, Barcelona, Spain
- Institució Catalana de Recerca i Estudis Avançats, E-08010 Barcelona, Spain
| | - R L C Ogando
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Observatório Nacional, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
| | - A Palmese
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - A A Plazas
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - A K Romer
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton BN1 9QH, United Kingdom
| | - A Roodman
- Kavli Institute for Particle Astrophysics and Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - E S Rykoff
- Kavli Institute for Particle Astrophysics and Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - C Sánchez
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - E Sanchez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - V Scarpine
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - S Serrano
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - I Sevilla-Noarbe
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - M Smith
- School of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, United Kingdom
| | - M Soares-Santos
- Brandeis University, Physics Department, 415 South Street, Waltham, Massachusetts 02453, USA
| | - F Sobreira
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua General José Cristino 77, Rio de Janeiro, RJ-20921-400, Brazil
- Instituto de Física Gleb Wataghin, Universidade Estadual de Campinas, 13083-859 Campinas, São Paulo, Brazil
| | - E Suchyta
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M E C Swanson
- National Center for Supercomputing Applications, 1205 West Clark Street, Urbana, Illinois 61801, USA
| | - G Tarle
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D Thomas
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - V Vikram
- Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois 60439, USA
| | - Y Zhang
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| |
Collapse
|
12
|
Raghunathan S, Patil S, Baxter E, Benson BA, Bleem LE, Crawford TM, Holder GP, McClintock T, Reichardt CL, Varga TN, Whitehorn N, Ade PAR, Allam S, Anderson AJ, Austermann JE, Avila S, Avva JS, Bacon D, Beall JA, Bender AN, Bianchini F, Bocquet S, Brooks D, Burke DL, Carlstrom JE, Carretero J, Castander FJ, Chang CL, Chiang HC, Citron R, Costanzi M, Crites AT, da Costa LN, Desai S, Diehl HT, Dietrich JP, Dobbs MA, Doel P, Everett S, Evrard AE, Feng C, Flaugher B, Fosalba P, Frieman J, Gallicchio J, García-Bellido J, Gaztanaga E, George EM, Giannantonio T, Gilbert A, Gruendl RA, Gschwend J, Gupta N, Gutierrez G, de Haan T, Halverson NW, Harrington N, Henning JW, Hilton GC, Hollowood DL, Holzapfel WL, Honscheid K, Hrubes JD, Huang N, Hubmayr J, Irwin KD, Jeltema T, Kind MC, Knox L, Kuropatkin N, Lahav O, Lee AT, Li D, Lima M, Lowitz A, Maia MAG, Marshall JL, McMahon JJ, Melchior P, Menanteau F, Meyer SS, Miquel R, Mocanu LM, Mohr JJ, Montgomery J, Moran CC, Nadolski A, Natoli T, Nibarger JP, Noble G, Novosad V, Ogando RLC, Padin S, Plazas AA, Pryke C, Rapetti D, Romer AK, Roodman A, Rosell AC, Rozo E, Ruhl JE, Rykoff ES, Saliwanchik BR, Sanchez E, Sayre JT, Scarpine V, Schaffer KK, Schubnell M, Serrano S, Sevilla-Noarbe I, Sievers C, Smecher G, Smith M, Soares-Santos M, Stark AA, Story KT, Suchyta E, Swanson MEC, Tarle G, Tucker C, Vanderlinde K, Veach T, De Vicente J, Vieira JD, Vikram V, Wang G, Wu WLK, Yefremenko V, Zhang Y. Detection of CMB-Cluster Lensing using Polarization Data from SPTpol. Phys Rev Lett 2019; 123:181301. [PMID: 31763885 DOI: 10.1103/physrevlett.123.181301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Indexed: 06/10/2023]
Abstract
We report the first detection of gravitational lensing due to galaxy clusters using only the polarization of the cosmic microwave background (CMB). The lensing signal is obtained using a new estimator that extracts the lensing dipole signature from stacked images formed by rotating the cluster-centered Stokes QU map cutouts along the direction of the locally measured background CMB polarization gradient. Using data from the SPTpol 500 deg^{2} survey at the locations of roughly 18 000 clusters with richness λ≥10 from the Dark Energy Survey (DES) Year-3 full galaxy cluster catalog, we detect lensing at 4.8σ. The mean stacked mass of the selected sample is found to be (1.43±0.40)×10^{14}M_{⊙} which is in good agreement with optical weak lensing based estimates using DES data and CMB-lensing based estimates using SPTpol temperature data. This measurement is a key first step for cluster cosmology with future low-noise CMB surveys, like CMB-S4, for which CMB polarization will be the primary channel for cluster lensing measurements.
Collapse
Affiliation(s)
- S Raghunathan
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
- School of Physics, University of Melbourne, Parkville VIC 3010, Australia
| | - S Patil
- School of Physics, University of Melbourne, Parkville VIC 3010, Australia
| | - E Baxter
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - B A Benson
- Fermi National Accelerator Laboratory, MS209, P.O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - L E Bleem
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - T M Crawford
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - G P Holder
- Astronomy Department, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- Department of Physics, University of Illinois Urbana-Champaign, 1110 W. Green Street, Urbana, Illinois 61801, USA
- Canadian Institute for Advanced Research, CIFAR Program in Gravity and the Extreme Universe, Toronto, Ontario M5G 1Z8, Canada
| | - T McClintock
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - C L Reichardt
- School of Physics, University of Melbourne, Parkville VIC 3010, Australia
| | - T N Varga
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, Garching 85748, Germany
- Universitäts-Sternwarte, Fakultät für Physik, LudwigMaximilians Universität München, Scheinerstr. 1, München 81679, Germany
| | - N Whitehorn
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - P A R Ade
- Cardiff University, Cardiff CF10 3XQ, United Kingdom
| | - S Allam
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - A J Anderson
- Fermi National Accelerator Laboratory, MS209, P.O. Box 500, Batavia, Illinois 60510, USA
| | - J E Austermann
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
| | - S Avila
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - J S Avva
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - D Bacon
- Institute of Cosmology & Gravitation, University of Portsmouth, Dennis Sciama Building, Burnaby Road, Portsmouth PO1 3FX, United Kingdom
| | - J A Beall
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
| | - A N Bender
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - F Bianchini
- School of Physics, University of Melbourne, Parkville VIC 3010, Australia
| | - S Bocquet
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, Munich 81679, Germany
| | - D Brooks
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - D L Burke
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - J E Carlstrom
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
- Department of Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Enrico Fermi Institute, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - J Carretero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) 08193, Spain
| | - F J Castander
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona 08034, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, Barcelona 08193, Spain
| | - C L Chang
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - H C Chiang
- School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Durban, Scottsville 3209, South Africa
| | - R Citron
- University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - M Costanzi
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, München 81679, Germany
| | - A T Crites
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- California Institute of Technology, MS 249-17, 1216 E. California Blvd., Pasadena, California 91125, USA
| | - L N da Costa
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - S Desai
- Department of Physics, IIT Hyderabad, Kandi, Telangana 502285, India
| | - H T Diehl
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J P Dietrich
- Excellence Cluster Origins, Boltzmannstr. 2, Garching 85748, Germany
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, Munich 81679, Germany
| | - M A Dobbs
- Canadian Institute for Advanced Research, CIFAR Program in Gravity and the Extreme Universe, Toronto, Ontario M5G 1Z8, Canada
- Department of Physics, McGill University, 3600 Rue University, Montreal, Quebec H3A 2T8, Canada
| | - P Doel
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - S Everett
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - A E Evrard
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - C Feng
- Astronomy Department, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- Department of Physics, University of Illinois Urbana-Champaign, 1110 W. Green Street, Urbana, Illinois 61801, USA
| | - B Flaugher
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - P Fosalba
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona 08034, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, Barcelona 08193, Spain
| | - J Frieman
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Gallicchio
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Harvey Mudd College, 301 Platt Blvd., Claremont, California 91711, USA
| | - J García-Bellido
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - E Gaztanaga
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona 08034, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, Barcelona 08193, Spain
| | - E M George
- Department of Physics, University of California, Berkeley, California 94720, USA
- European Southern Observatory, Karl-Schwarzschild-Str. 2, Garching bei München 85748, Germany
| | - T Giannantonio
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
| | - A Gilbert
- Department of Physics, McGill University, 3600 Rue University, Montreal, Quebec H3A 2T8, Canada
| | - R A Gruendl
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - J Gschwend
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - N Gupta
- School of Physics, University of Melbourne, Parkville VIC 3010, Australia
| | - G Gutierrez
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - T de Haan
- Department of Physics, University of California, Berkeley, California 94720, USA
- Physics Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N W Halverson
- Department of Astrophysical and Planetary Sciences, University of Colorado, Boulder, Colorado 80309, USA
- Department of Physics, University of Colorado, Boulder, Colorado 80309, USA
| | - N Harrington
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J W Henning
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - G C Hilton
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
| | - D L Hollowood
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - W L Holzapfel
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - K Honscheid
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - J D Hrubes
- University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - N Huang
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - J Hubmayr
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
| | - K D Irwin
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
- Deptartment of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - T Jeltema
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - M Carrasco Kind
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - L Knox
- Department of Physics, University of California, One Shields Avenue, Davis, California 95616, USA
| | - N Kuropatkin
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - O Lahav
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - A T Lee
- Department of Physics, University of California, Berkeley, California 94720, USA
- Physics Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D Li
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
- SLAC National Accelerator Laboratory, 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - M Lima
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP 05314-970, Brazil
| | - A Lowitz
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - M A G Maia
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - J J McMahon
- Department of Physics, University of Michigan, 450 Church Street, Ann Arbor, Michigan 48109, USA
| | - P Melchior
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - F Menanteau
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - S S Meyer
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Enrico Fermi Institute, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - R Miquel
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) 08193, Spain
- Institució Catalana de Recerca i Estudis Avançats, Barcelona E-08010, Spain
| | - L M Mocanu
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - J J Mohr
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, Garching 85748, Germany
- Excellence Cluster Origins, Boltzmannstr. 2, Garching 85748, Germany
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, Munich 81679, Germany
| | - J Montgomery
- Department of Physics, McGill University, 3600 Rue University, Montreal, Quebec H3A 2T8, Canada
| | - C Corbett Moran
- TAPIR, Walter Burke Institute for Theoretical Physics, California Institute of Technology, 1200 E California Blvd, Pasadena, California 91125, USA
| | - A Nadolski
- Astronomy Department, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- Department of Physics, University of Illinois Urbana-Champaign, 1110 W. Green Street, Urbana, Illinois 61801, USA
| | - T Natoli
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Dunlap Institute for Astronomy & Astrophysics, University of Toronto, 50 St George St, Toronto, Ontario M5S 3H4, Canada
| | - J P Nibarger
- NIST Quantum Devices Group, 325 Broadway Mailcode 817.03, Boulder, Colorado 80305, USA
| | - G Noble
- Department of Physics, McGill University, 3600 Rue University, Montreal, Quebec H3A 2T8, Canada
| | - V Novosad
- Materials Sciences Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - R L C Ogando
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - S Padin
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Department of Astronomy and Astrophysics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- California Institute of Technology, MS 249-17, 1216 E. California Blvd., Pasadena, California 91125, USA
| | - A A Plazas
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - C Pryke
- School of Physics and Astronomy, University of Minnesota, 116 Church Street S.E. Minneapolis, Minneapolis 55455, USA
| | - D Rapetti
- Department of Astrophysical and Planetary Sciences, University of Colorado, Boulder, Colorado 80309, USA
- NASA Postdoctoral Program Senior Fellow, NASA Ames Research Center, Moffett Field, California 94035, USA
| | - A K Romer
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton BN1 9QH, United Kingdom
| | - A Roodman
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - A Carnero Rosell
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain
| | - E Rozo
- Department of Physics, University of Arizona, Tucson, Arizona 85721, USA
| | - J E Ruhl
- Physics Department, Center for Education and Research in Cosmology and Astrophysics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | - E S Rykoff
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - B R Saliwanchik
- Physics Department, Center for Education and Research in Cosmology and Astrophysics, Case Western Reserve University, Cleveland, Ohio 44106, USA
- Department of Physics, Yale University, P.O. Box 208120, New Haven, Connecticut 06520-8120, USA
| | - E Sanchez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain
| | - J T Sayre
- Department of Astrophysical and Planetary Sciences, University of Colorado, Boulder, Colorado 80309, USA
- Department of Physics, University of Colorado, Boulder, Colorado 80309, USA
| | - V Scarpine
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - K K Schaffer
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Enrico Fermi Institute, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
- Liberal Arts Department, School of the Art Institute of Chicago, 112 S Michigan Ave, Chicago, Illinois 60603, USA
| | - M Schubnell
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - S Serrano
- Institut d'Estudis Espacials de Catalunya (IEEC), Barcelona 08034, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, Barcelona 08193, Spain
| | - I Sevilla-Noarbe
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain
| | - C Sievers
- University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - G Smecher
- Department of Physics, McGill University, 3600 Rue University, Montreal, Quebec H3A 2T8, Canada
- Three-Speed Logic, Inc., Vancouver, British Columbia V6A 2J8, Canada
| | - M Smith
- School of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, United Kingdom
| | - M Soares-Santos
- Brandeis University, Physics Department, 415 South Street, Waltham Massachusetts 02453, USA
| | - A A Stark
- Harvard-Smithsonian Center for Astrophysics, 60 Garden Street, Cambridge, Massachusetts 02138, USA
| | - K T Story
- Deptartment of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, 452 Lomita Mall, Stanford, California 94305, USA
| | - E Suchyta
- Computer Science and Mathematics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M E C Swanson
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - G Tarle
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - C Tucker
- Cardiff University, Cardiff CF10 3XQ, United Kingdom
| | - K Vanderlinde
- Dunlap Institute for Astronomy & Astrophysics, University of Toronto, 50 St George St, Toronto, Ontario M5S 3H4, Canada
- Department of Astronomy and Astrophysics, University of Toronto, 50 St George St, Toronto, Ontario M5S 3H4, Canada
| | - T Veach
- Department of Astronomy, University of Maryland College Park, Maryland 20742, USA
| | - J De Vicente
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid 28040, Spain
| | - J D Vieira
- Astronomy Department, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- Department of Physics, University of Illinois Urbana-Champaign, 1110 W. Green Street, Urbana, Illinois 61801, USA
| | - V Vikram
- Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois 60439, USA
| | - G Wang
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - W L K Wu
- Kavli Institute for Cosmological Physics, University of Chicago, 5640 South Ellis Avenue, Chicago, Illinois 60637, USA
| | - V Yefremenko
- High Energy Physics Division, Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, Illinois 60439, USA
| | - Y Zhang
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| |
Collapse
|
13
|
Abbott TMC, Alarcon A, Allam S, Andersen P, Andrade-Oliveira F, Annis J, Asorey J, Avila S, Bacon D, Banik N, Bassett BA, Baxter E, Bechtol K, Becker MR, Bernstein GM, Bertin E, Blazek J, Bridle SL, Brooks D, Brout D, Burke DL, Calcino J, Camacho H, Campos A, Carnero Rosell A, Carollo D, Carrasco Kind M, Carretero J, Castander FJ, Cawthon R, Challis P, Chan KC, Chang C, Childress M, Crocce M, Cunha CE, D'Andrea CB, da Costa LN, Davis C, Davis TM, De Vicente J, DePoy DL, DeRose J, Desai S, Diehl HT, Dietrich JP, Dodelson S, Doel P, Drlica-Wagner A, Eifler TF, Elvin-Poole J, Estrada J, Evrard AE, Fernandez E, Flaugher B, Foley RJ, Fosalba P, Frieman J, Galbany L, García-Bellido J, Gatti M, Gaztanaga E, Gerdes DW, Giannantonio T, Glazebrook K, Goldstein DA, Gruen D, Gruendl RA, Gschwend J, Gutierrez G, Hartley WG, Hinton SR, Hollowood DL, Honscheid K, Hoormann JK, Hoyle B, Huterer D, Jain B, James DJ, Jarvis M, Jeltema T, Kasai E, Kent S, Kessler R, Kim AG, Kokron N, Krause E, Kron R, Kuehn K, Kuropatkin N, Lahav O, Lasker J, Lemos P, Lewis GF, Li TS, Lidman C, Lima M, Lin H, Macaulay E, MacCrann N, Maia MAG, March M, Marriner J, Marshall JL, Martini P, McMahon RG, Melchior P, Menanteau F, Miquel R, Mohr JJ, Morganson E, Muir J, Möller A, Neilsen E, Nichol RC, Nord B, Ogando RLC, Palmese A, Pan YC, Peiris HV, Percival WJ, Plazas AA, Porredon A, Prat J, Romer AK, Roodman A, Rosenfeld R, Ross AJ, Rykoff ES, Samuroff S, Sánchez C, Sanchez E, Scarpine V, Schindler R, Schubnell M, Scolnic D, Secco LF, Serrano S, Sevilla-Noarbe I, Sharp R, Sheldon E, Smith M, Soares-Santos M, Sobreira F, Sommer NE, Swann E, Swanson MEC, Tarle G, Thomas D, Thomas RC, Troxel MA, Tucker BE, Uddin SA, Vielzeuf P, Walker AR, Wang M, Weaverdyck N, Wechsler RH, Weller J, Yanny B, Zhang B, Zhang Y, Zuntz J. Cosmological Constraints from Multiple Probes in the Dark Energy Survey. Phys Rev Lett 2019; 122:171301. [PMID: 31107093 DOI: 10.1103/physrevlett.122.171301] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 02/19/2019] [Indexed: 06/09/2023]
Abstract
The combination of multiple observational probes has long been advocated as a powerful technique to constrain cosmological parameters, in particular dark energy. The Dark Energy Survey has measured 207 spectroscopically confirmed type Ia supernova light curves, the baryon acoustic oscillation feature, weak gravitational lensing, and galaxy clustering. Here we present combined results from these probes, deriving constraints on the equation of state, w, of dark energy and its energy density in the Universe. Independently of other experiments, such as those that measure the cosmic microwave background, the probes from this single photometric survey rule out a Universe with no dark energy, finding w=-0.80_{-0.11}^{+0.09}. The geometry is shown to be consistent with a spatially flat Universe, and we obtain a constraint on the baryon density of Ω_{b}=0.069_{-0.012}^{+0.009} that is independent of early Universe measurements. These results demonstrate the potential power of large multiprobe photometric surveys and pave the way for order of magnitude advances in our constraints on properties of dark energy and cosmology over the next decade.
Collapse
Affiliation(s)
- T M C Abbott
- Cerro Tololo Inter-American Observatory, National Optical Astronomy Observatory, Casilla 603, La Serena, Chile
| | - A Alarcon
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - S Allam
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - P Andersen
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
- University of Copenhagen, Dark Cosmology Centre, Juliane Maries Vej 30, 2100 Copenhagen O, Denmark
| | - F Andrade-Oliveira
- Instituto de Física Teórica, Universidade Estadual Paulista, São Paulo, Brazil
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - J Annis
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J Asorey
- Korea Astronomy and Space Science Institute, Yuseong-gu, Daejeon 305-348, Korea
| | - S Avila
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - D Bacon
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - N Banik
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - B A Bassett
- African Institute for Mathematical Sciences, 6 Melrose Road, Muizenberg 7945, South Africa
- South African Astronomical Observatory, P.O.Box 9, Observatory 7935, South Africa
| | - E Baxter
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - K Bechtol
- LSST, 933 North Cherry Avenue, Tucson, Arizona 85721, USA
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue Madison, Wisconsin 53706-1390, USA
| | - M R Becker
- Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois 60439, USA
| | - G M Bernstein
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - E Bertin
- CNRS, UMR 7095, Institut d'Astrophysique de Paris, F-75014 Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, UMR 7095, Institut d'Astrophysique de Paris, F-75014 Paris, France
| | - J Blazek
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Institute of Physics, Laboratory of Astrophysics, École Polytechnique Fédérale de Lausanne (EPFL), Observatoire de Sauverny, 1290 Versoix, Switzerland
| | - S L Bridle
- Jodrell Bank Center for Astrophysics, School of Physics and Astronomy, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
| | - D Brooks
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - D Brout
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - D L Burke
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - J Calcino
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - H Camacho
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP 05314-970, Brazil
| | - A Campos
- Instituto de Física Teórica, Universidade Estadual Paulista, São Paulo, Brazil
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - A Carnero Rosell
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - D Carollo
- INAF, Astrophysical Observatory of Turin, I-10025 Pino Torinese, Italy
| | - M Carrasco Kind
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - J Carretero
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - F J Castander
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - R Cawthon
- Physics Department, 2320 Chamberlin Hall, University of Wisconsin-Madison, 1150 University Avenue Madison, Wisconsin 53706-1390, USA
| | - P Challis
- Harvard-Smithsonian Center for Astrophysics, 60 Garden St., Cambridge, Massachusetts 02138, USA
| | - K C Chan
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - C Chang
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Childress
- School of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, United Kingdom
| | - M Crocce
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - C E Cunha
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - C B D'Andrea
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - L N da Costa
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - C Davis
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - T M Davis
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - J De Vicente
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - D L DePoy
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - J DeRose
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - S Desai
- Department of Physics, IIT Hyderabad, Kandi, Telangana 502285, India
| | - H T Diehl
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J P Dietrich
- Excellence Cluster Universe, Boltzmannstr. 2, 85748 Garching, Germany
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, 81679 Munich, Germany
| | - S Dodelson
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - P Doel
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - A Drlica-Wagner
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - T F Eifler
- Department of Astronomy/Steward Observatory, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
- Jet Propulsion Laboratory, California Institute of Technology, 4800 Oak Grove Dr., Pasadena, California 91109, USA
| | - J Elvin-Poole
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - J Estrada
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - A E Evrard
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - E Fernandez
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - B Flaugher
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - R J Foley
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - P Fosalba
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - J Frieman
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - L Galbany
- PITT PACC, Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | - J García-Bellido
- Instituto de Fisica Teorica UAM/CSIC, Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - M Gatti
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - E Gaztanaga
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - D W Gerdes
- Department of Astronomy, University of Michigan, Ann Arbor, Michigan 48109, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - T Giannantonio
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kindom
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
| | - K Glazebrook
- Centre for Astrophysics & Supercomputing, Swinburne University of Technology, VIC 3122, Australia
| | - D A Goldstein
- California Institute of Technology, 1200 East California Blvd, MC 249-17, Pasadena, California 91125, USA
| | - D Gruen
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - R A Gruendl
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - J Gschwend
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - G Gutierrez
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - W G Hartley
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Department of Physics, ETH Zurich, Wolfgang-Pauli-Strasse 16, CH-8093 Zurich, Switzerland
| | - S R Hinton
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - D L Hollowood
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - K Honscheid
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - J K Hoormann
- School of Mathematics and Physics, University of Queensland, Brisbane, QLD 4072, Australia
| | - B Hoyle
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
| | - D Huterer
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - B Jain
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - D J James
- Harvard-Smithsonian Center for Astrophysics, Cambridge, Massachusetts 02138, USA
| | - M Jarvis
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - T Jeltema
- Santa Cruz Institute for Particle Physics, Santa Cruz, California 95064, USA
| | - E Kasai
- South African Astronomical Observatory, P.O.Box 9, Observatory 7935, South Africa
- Department of Physics, University of Namibia, 340 Mandume Ndemufayo Avenue, Pionierspark, Windhoek, Namibia
| | - S Kent
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - R Kessler
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - A G Kim
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720, USA
| | - N Kokron
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - E Krause
- Department of Astronomy/Steward Observatory, 933 North Cherry Avenue, Tucson, Arizona 85721-0065, USA
| | - R Kron
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - K Kuehn
- Australian Astronomical Optics, Macquarie University, North Ryde, NSW 2113, Australia
| | - N Kuropatkin
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - O Lahav
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - J Lasker
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, Illinois 60637, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - P Lemos
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kindom
| | - G F Lewis
- Sydney Institute for Astronomy, School of Physics, A28, The University of Sydney, NSW 2006, Australia
| | - T S Li
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
- Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C Lidman
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
| | - M Lima
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Departamento de Física Matemática, Instituto de Física, Universidade de São Paulo, CP 66318, São Paulo, SP 05314-970, Brazil
| | - H Lin
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - E Macaulay
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - N MacCrann
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - M A G Maia
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - M March
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - J Marriner
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - P Martini
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
- Department of Astronomy, The Ohio State University, Columbus, Ohio 43210, USA
| | - R G McMahon
- Institute of Astronomy, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kingdom
- Kavli Institute for Cosmology, University of Cambridge, Madingley Road, Cambridge CB3 0HA, United Kindom
| | - P Melchior
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - F Menanteau
- Department of Astronomy, University of Illinois at Urbana-Champaign, 1002 W. Green Street, Urbana, Illinois 61801, USA
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - R Miquel
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
- Institució Catalana de Recerca i Estudis Avançats, E-08010 Barcelona, Spain
| | - J J Mohr
- Excellence Cluster Universe, Boltzmannstr. 2, 85748 Garching, Germany
- Faculty of Physics, Ludwig-Maximilians-Universität, Scheinerstr. 1, 81679 Munich, Germany
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
| | - E Morganson
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - J Muir
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
| | - A Möller
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
- ARC Centre of Excellence for All-sky Astrophysics (CAASTRO), Millers Point, NSW 2000, Australia
| | - E Neilsen
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - R C Nichol
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - B Nord
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - R L C Ogando
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Observatório Nacional, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
| | - A Palmese
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - Y-C Pan
- Division of Theoretical Astronomy, National Astronomical Observatory of Japan, 2-21-1 Osawa, Mitaka, Tokyo 181-8588, Japan
- Institute of Astronomy and Astrophysics, Academia Sinica, Taipei 10617, Taiwan
| | - H V Peiris
- Department of Physics & Astronomy, University College London, Gower Street, London WC1E 6BT, United Kingdom
| | - W J Percival
- Department of Physics and Astronomy, University of Waterloo, 200 University Ave W, Waterloo, Ontario N2L 3G1, Canada
- Perimeter Institute for Theoretical Physics, 31 Caroline St. North, Waterloo, Ontario N2L 2Y5, Canada
| | - A A Plazas
- Department of Astrophysical Sciences, Princeton University, Peyton Hall, Princeton, New Jersey 08544, USA
| | - A Porredon
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - J Prat
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - A K Romer
- Department of Physics and Astronomy, Pevensey Building, University of Sussex, Brighton BN1 9QH, United Kingdom
| | - A Roodman
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - R Rosenfeld
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- ICTP South American Institute for Fundamental Research Instituto de Física Teórica, Universidade Estadual Paulista, São Paulo, Brazil
| | - A J Ross
- Center for Cosmology and Astro-Particle Physics, The Ohio State University, Columbus, Ohio 43210, USA
| | - E S Rykoff
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Samuroff
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15312, USA
| | - C Sánchez
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - E Sanchez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - V Scarpine
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - R Schindler
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Schubnell
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D Scolnic
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - L F Secco
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - S Serrano
- Institut d'Estudis Espacials de Catalunya (IEEC), 08034 Barcelona, Spain
- Institute of Space Sciences (ICE, CSIC), Campus UAB, Carrer de Can Magrans, s/n, 08193 Barcelona, Spain
| | - I Sevilla-Noarbe
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Sharp
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
| | - E Sheldon
- Brookhaven National Laboratory, Bldg 510, Upton, New York 11973, USA
| | - M Smith
- School of Physics and Astronomy, University of Southampton, Southampton SO17 1BJ, United Kingdom
| | - M Soares-Santos
- Brandeis University, Physics Department, 415 South Street, Waltham, Massachusetts 02453, USA
| | - F Sobreira
- Laboratório Interinstitucional de e-Astronomia-LIneA, Rua Gal. José Cristino 77, Rio de Janeiro, RJ 20921-400, Brazil
- Instituto de Física Gleb Wataghin, Universidade Estadual de Campinas, 13083-859 Campinas, SP, Brazil
| | - N E Sommer
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
- ARC Centre of Excellence for All-sky Astrophysics (CAASTRO), Millers Point, NSW 2000, Australia
| | - E Swann
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - M E C Swanson
- National Center for Supercomputing Applications, 1205 West Clark St., Urbana, Illinois 61801, USA
| | - G Tarle
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - D Thomas
- Institute of Cosmology and Gravitation, University of Portsmouth, Portsmouth PO1 3FX, United Kingdom
| | - R C Thomas
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720, USA
| | - M A Troxel
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - B E Tucker
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
- ARC Centre of Excellence for All-sky Astrophysics (CAASTRO), Millers Point, NSW 2000, Australia
| | - S A Uddin
- Observatories of the Carnegie Institution for Science, 813 Santa Barbara St., Pasadena, California 91101, USA
| | - P Vielzeuf
- Institut de Física d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, 08193 Bellaterra (Barcelona) Spain
| | - A R Walker
- Cerro Tololo Inter-American Observatory, National Optical Astronomy Observatory, Casilla 603, La Serena, Chile
| | - M Wang
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - N Weaverdyck
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - R H Wechsler
- Kavli Institute for Particle Astrophysics & Cosmology, P. O. Box 2450, Stanford University, Stanford, California 94305, USA
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
- Department of Physics, Stanford University, 382 Via Pueblo Mall, Stanford, California 94305, USA
| | - J Weller
- Excellence Cluster Universe, Boltzmannstr. 2, 85748 Garching, Germany
- Universitäts-Sternwarte, Fakultät für Physik, Ludwig-Maximilians Universität München, Scheinerstr. 1, 81679 München, Germany
- Max Planck Institute for Extraterrestrial Physics, Giessenbachstrasse, 85748 Garching, Germany
| | - B Yanny
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - B Zhang
- The Research School of Astronomy and Astrophysics, Australian National University, ACT 2601, Australia
- ARC Centre of Excellence for All-sky Astrophysics (CAASTRO), Millers Point, NSW 2000, Australia
| | - Y Zhang
- Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, Illinois 60510, USA
| | - J Zuntz
- Institute for Astronomy, University of Edinburgh, Edinburgh EH9 3HJ, United Kingdom
| |
Collapse
|
14
|
Manjaly Thomas ZR, Satti I, Marshall JL, Harris SA, Lopez Ramon R, Hamidi A, Minhinnick A, Riste M, Stockdale L, Lawrie AM, Vermaak S, Wilkie M, Bettinson H, McShane H. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Med 2019; 16:e1002790. [PMID: 31039172 PMCID: PMC6490884 DOI: 10.1371/journal.pmed.1002790] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 03/26/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (Ag85A). METHODS AND FINDINGS Between December 2013 and January 2016, 36 bacille Calmette-Guérin-vaccinated, healthy UK adults were randomised equally between 3 groups to receive 2 MVA85A vaccinations 1 month apart using either heterologous (Group 1, aerosol-intradermal; Group 2, intradermal-aerosol) or homologous (Group 3, intradermal-intradermal) immunisation. Bronchoscopy and bronchoalveolar lavage (BAL) were performed 7 days post-vaccination. Adverse events (AEs) and peripheral blood were collected for 6 months post-vaccination. The laboratory and bronchoscopy teams were blinded to treatment allocation. One participant was withdrawn and was replaced. Participants were aged 21-42 years, and 28/37 were female. In a per protocol analysis, aerosol delivery of MVA85A as a priming immunisation was well tolerated and highly immunogenic. Most AEs were mild local injection site reactions following intradermal vaccination. Transient systemic AEs occurred following vaccination by both routes and were most frequently mild. All respiratory AEs following primary aerosol MVA85A (Group 1) were mild. Boosting an intradermal MVA85A prime with an aerosolised MVA85A boost 1 month later (Group 2) resulted in transient moderate/severe respiratory and systemic AEs. There were no serious adverse events and no bronchoscopy-related complications. Only the intradermal-aerosol vaccination regimen (Group 2) resulted in modest, significant boosting of the cell-mediated immune response to Ag85A (p = 0.027; 95% CI: 28 to 630 spot forming cells per 1 × 106 peripheral blood mononuclear cells). All 3 regimens induced systemic cellular immune responses to the modified vaccinia virus Ankara (MVA) vector. Serum antibodies to Ag85A and MVA were only induced after intradermal vaccination. Aerosolised MVA85A induced significantly higher levels of Ag85A lung mucosal CD4+ and CD8+ T cell cytokines compared to intradermal vaccination. Boosting with aerosol-inhaled MVA85A enhanced the intradermal primed responses in Group 2. The magnitude of BAL MVA-specific CD4+ T cell responses was lower than the Ag85A-specific responses. A limitation of the study is that while the intradermal-aerosol regimen induced the most potent cellular Ag85A immune responses, we did not boost the last 3 participants in this group because of the AE profile. Timing of bronchoscopies aimed to capture peak mucosal response; however, peak responses may have occurred outside of this time frame. CONCLUSIONS To our knowledge, this is the first human randomised clinical trial to explore heterologous prime-boost regimes using aerosol and systemic routes of administration of a virally vectored vaccine. In this trial, the aerosol prime-intradermal boost regime was well tolerated, but intradermal prime-aerosol boost resulted in transient but significant respiratory AEs. Aerosol vaccination induced potent cellular Ag85A-specific mucosal and systemic immune responses. Whilst the implications of inducing potent mucosal and systemic immunity for protection are unclear, these findings are of relevance for the development of aerosolised vaccines for TB and other respiratory and mucosal pathogens. TRIAL REGISTRATION ClinicalTrials.gov NCT01954563.
Collapse
Affiliation(s)
- Zita-Rose Manjaly Thomas
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Iman Satti
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Julia L. Marshall
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Stephanie A. Harris
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Raquel Lopez Ramon
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Ali Hamidi
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Alice Minhinnick
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Michael Riste
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Lisa Stockdale
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Alison M. Lawrie
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Samantha Vermaak
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Morven Wilkie
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Henry Bettinson
- Oxford Centre for Respiratory Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| | - Helen McShane
- Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
15
|
Flores-Langarica A, Müller Luda K, Persson EK, Cook CN, Bobat S, Marshall JL, Dahlgren MW, Hägerbrand K, Toellner KM, Goodall MD, Withers DR, Henderson IR, Johansson Lindbom B, Cunningham AF, Agace WW. CD103 +CD11b + mucosal classical dendritic cells initiate long-term switched antibody responses to flagellin. Mucosal Immunol 2018; 11:681-692. [PMID: 29346347 PMCID: PMC5912514 DOI: 10.1038/mi.2017.105] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 10/23/2017] [Indexed: 02/04/2023]
Abstract
Antibody responses induced at mucosal and nonmucosal sites demonstrate a significant level of autonomy. Here, we demonstrate a key role for mucosal interferon regulatory factor-4 (IRF4)-dependent CD103+CD11b+ (DP), classical dendritic cells (cDCs) in the induction of T-dependent immunoglobulin G (IgG) and immunoglobulin A (IgA) responses in the mesenteric lymph node (MLN) following systemic immunization with soluble flagellin (sFliC). In contrast, IRF8-dependent CD103+CD11b- (SP) are not required for these responses. The lack of this response correlated with a complete absence of sFliC-specific plasma cells in the MLN, small intestinal lamina propria, and surprisingly also the bone marrow (BM). Many sFliC-specific plasma cells accumulating in the BM of immunized wild-type mice expressed α4β7+, suggesting a mucosal origin. Collectively, these results suggest that mucosal DP cDC contribute to the generation of the sFliC-specific plasma cell pool in the BM and thus serve as a bridge linking the mucosal and systemic immune system.
Collapse
Affiliation(s)
- A Flores-Langarica
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - K Müller Luda
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
| | - E K Persson
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
| | - C N Cook
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - S Bobat
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - J L Marshall
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - M W Dahlgren
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
| | - K Hägerbrand
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
| | - K M Toellner
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - M D Goodall
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - D R Withers
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - I R Henderson
- Institute of Microbiology and Infection, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - B Johansson Lindbom
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
- Division of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark (DTU). Kongens Lyngby, Denmark
| | - A F Cunningham
- Institute of Immunology & Immunotherapy, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
- Institute of Microbiology and Infection, College of Medical & Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - W W Agace
- Immunology Section, Lund University, BMC D14 Sölvegatan 19, S-221 84. Lund 22184, Sweden
- Division of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark (DTU). Kongens Lyngby, Denmark
| |
Collapse
|
16
|
Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang R, Xiao N, Greil R, Rinnerthaler G, Gampenrieder S, Heimberger AB, Berry DJ, Barker A, Demetri GD, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Miglarese MR, Famulok M, Mayer G, Spetzler D. Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Deconvolution of multi-nodal perturbations in cancer network architecture demands highly multiplexed profiling assays. We demonstrate the value of polyligand profiling of tumor systems states using libraries of single stranded oligodeoxynucleotides (ssODN) to distinguish between tumor tissue from breast cancer patients who did or did not derive benefit from treatment regimens containing trastuzumab.
Methods: This study included cases from women with invasive breast cancer who received chemotherapy+ trastuzumab (C+T) or trastuzumab monotherapy with available retrospective data on the time to next treatment (TTNT). A library of 2x1012 unique ssODN was exposed to FFPE tissues from patients who benefited (B) or not (NB) from trastuzumab-based regimens in several rounds of positive and negative selection. Two enriched libraries were screened on independent set of 42 B and 19 NB cases using a modified IHC protocol for detection of bound ssODNs. Poly-Ligand Profiles (PLP) were scored by a blinded pathologist. Two libraries, EL-NB and EL-B, showed significant p-values between groups of responders and non-responders. A Cox-PH model was fitted using either tumors' HER2 status or PLP test results as the independent variable. Median survival time was calculated from the Kaplan-Meier estimate. A separate group of 63 cases with TTNT data from chemotherapy without trastuzumab was used as a control to distinguish prognostic from predictive performance.
Results: The PLP scores of EL-NB and EL-B were assessed by receiver operating characteristic (ROC) curves and resulted in a combined AUC value of 0.81. EL-NB and EL-B were able to effectively classify B and NB patients with either HER2-negative/equivocal (AUC = 0.73) or HER2-positive cancers (AUC = 0.84). In contrast, HER2 status alone yielded an AUC value of 0.47. The combined PLP scores for the independent set of 63 patients treated with C excluding trastuzumab resulted in an AUC value of 0.53, indicating that the assay was predictive and not simply prognostic. Kaplan-Meier curves analysis shows that PLP+ cases have 429 days median TTNT, while PLP- cases have 129 days (HR = 0.38, log-rank p = 0.001). Analysis based on HER2 status showed no significant difference in TTNT between patients that were HER2+ (280 days) or HER2-negative/equivocal (336 days, HR = 1.27, log-rank p =0.45).
Summary: Performance of the PLP assay in differentiating patients who did or did not benefit from trastuzumab therapy outperforms the standard IHC assay for HER2 status. These results represent a promising step towards the development of a CDx to identify the 50-70% of HER2+ patients who will not benefit from trastuzumab. In addition, PLP also has the potential to identify the HER2-negative/equivocal patients who may benefit from trastuzumab-containing regimens.
Citation Format: Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang R, Xiao N, Greil R, Rinnerthaler G, Gampenrieder S, Heimberger AB, Berry DJ, Barker A, Demetri GD, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Miglarese MR, Famulok M, Mayer G, Spetzler D. Polyligand profiling differentiates cancer patients according to their benefit of treatment [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-09.
Collapse
Affiliation(s)
- V Domenyuk
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - Z Gatalica
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Santhanam
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - X Wei
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Stark
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - P Kennedy
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - B Toussaint
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - S Levenberg
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Wang
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - N Xiao
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - R Greil
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Rinnerthaler
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - S Gampenrieder
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - AB Heimberger
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - DJ Berry
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Barker
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - GD Demetri
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - J Quackenbush
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - JL Marshall
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Poste
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - JL Vacirca
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - GA Vidal
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - LS Schwartzberg
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - DD Halbert
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - A Voss
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - MR Miglarese
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - M Famulok
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - G Mayer
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| | - D Spetzler
- Caris Life Sciences, Phoenix, AZ; Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria; University of Texas MD Anderson Cancer Center, Houston, TX; Complex Adaptive Systems Initiative, Arizona State University, Scottsdale, AZ; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, Boston, MA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; North Shore Hematology Oncology Associates Cancer Center, New York, NY; University of Tennessee Health Science Center, Memphis, TN; LIMES Program Unit Chemical Biology & Medicinal Chemistry, c/o Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany; Chemical Biology Max-Planck-Fellowship Group, Center of Advanced European Studies and Research (CAESAR, Bonn, Germany; Center of Aptamer Research and Development, University of Bonn, Bonn, Germany
| |
Collapse
|
17
|
Shappee BJ, Simon JD, Drout MR, Piro AL, Morrell N, Prieto JL, Kasen D, Holoien TWS, Kollmeier JA, Kelson DD, Coulter DA, Foley RJ, Kilpatrick CD, Siebert MR, Madore BF, Murguia-Berthier A, Pan YC, Prochaska JX, Ramirez-Ruiz E, Rest A, Adams C, Alatalo K, Bañados E, Baughman J, Bernstein RA, Bitsakis T, Boutsia K, Bravo JR, Di Mille F, Higgs CR, Ji AP, Maravelias G, Marshall JL, Placco VM, Prieto G, Wan Z. Early spectra of the gravitational wave source GW170817: Evolution of a neutron star merger. Science 2017; 358:1574-1578. [PMID: 29038374 DOI: 10.1126/science.aaq0186] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 10/11/2017] [Indexed: 11/02/2022]
Abstract
On 17 August 2017, Swope Supernova Survey 2017a (SSS17a) was discovered as the optical counterpart of the binary neutron star gravitational wave event GW170817. We report time-series spectroscopy of SSS17a from 11.75 hours until 8.5 days after the merger. Over the first hour of observations, the ejecta rapidly expanded and cooled. Applying blackbody fits to the spectra, we measured the photosphere cooling from [Formula: see text] to [Formula: see text] kelvin, and determined a photospheric velocity of roughly 30% of the speed of light. The spectra of SSS17a began displaying broad features after 1.46 days and evolved qualitatively over each subsequent day, with distinct blue (early-time) and red (late-time) components. The late-time component is consistent with theoretical models of r-process-enriched neutron star ejecta, whereas the blue component requires high-velocity, lanthanide-free material.
Collapse
Affiliation(s)
- B J Shappee
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA. .,Institute for Astronomy, University of Hawai'i, 2680 Woodlawn Drive, Honolulu, HI 96822, USA
| | - J D Simon
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - M R Drout
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - A L Piro
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - N Morrell
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - J L Prieto
- Núcleo de Astronomía de la Facultad de Ingeniería y Ciencias, Universidad Diego Portales, Avenida Ejército 441, Santiago, Chile.,Millennium Institute of Astrophysics, Santiago, Chile
| | - D Kasen
- Departments of Physics and Astronomy, 366 LeConte Hall, University of California---Berkeley, Berkeley, CA 94720, USA.,Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - T W-S Holoien
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - J A Kollmeier
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - D D Kelson
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - D A Coulter
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - R J Foley
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - C D Kilpatrick
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - M R Siebert
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - B F Madore
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - A Murguia-Berthier
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - Y-C Pan
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - J X Prochaska
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA
| | - E Ramirez-Ruiz
- Department of Astronomy and Astrophysics, University of California-Santa Cruz, Santa Cruz, CA 95064, USA.,Dark Cosmology Center, Niels Bohr Institute, University of Copenhagen, Blegdamsvej 17, 2100 Copenhagen, Denmark
| | - A Rest
- Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA.,Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA
| | - C Adams
- Division of Physics, Mathematics, and Astronomy, California Institute of Technology, Pasadena, CA 91125, USA
| | - K Alatalo
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.,Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA
| | - E Bañados
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - J Baughman
- Núcleo de Astronomía de la Facultad de Ingeniería y Ciencias, Universidad Diego Portales, Avenida Ejército 441, Santiago, Chile.,Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - R A Bernstein
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - T Bitsakis
- Instituto de Radioastronomía y Astrofísica, Universidad Nacional Autónoma de México, C.P. 58190, Morelia, Mexico
| | - K Boutsia
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - J R Bravo
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - F Di Mille
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - C R Higgs
- University of Victoria, Victoria, BC V8P 5C2, Canada.,National Research Council (NRC) Herzberg Institute of Astrophysics, 5071 West Saanich Road, Victoria, BC V9E 2E7, Canada
| | - A P Ji
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.,Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA
| | - G Maravelias
- Instituto de Física y Astronomía, Universidad de Valparaíso, Valparaíso, Chile
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy and Department of Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - V M Placco
- Department of Physics and Joint Institute for Nuclear Astrophysics (JINA) Center for the Evolution of the Elements, University of Notre Dame, Notre Dame, IN 46556, USA
| | - G Prieto
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - Z Wan
- Sydney Institute for Astronomy, School of Physics, A28, University of Sydney, NSW 2006, Australia
| |
Collapse
|
18
|
Drout MR, Piro AL, Shappee BJ, Kilpatrick CD, Simon JD, Contreras C, Coulter DA, Foley RJ, Siebert MR, Morrell N, Boutsia K, Di Mille F, Holoien TWS, Kasen D, Kollmeier JA, Madore BF, Monson AJ, Murguia-Berthier A, Pan YC, Prochaska JX, Ramirez-Ruiz E, Rest A, Adams C, Alatalo K, Bañados E, Baughman J, Beers TC, Bernstein RA, Bitsakis T, Campillay A, Hansen TT, Higgs CR, Ji AP, Maravelias G, Marshall JL, Bidin CM, Prieto JL, Rasmussen KC, Rojas-Bravo C, Strom AL, Ulloa N, Vargas-González J, Wan Z, Whitten DD. Light curves of the neutron star merger GW170817/SSS17a: Implications for r-process nucleosynthesis. Science 2017; 358:1570-1574. [PMID: 29038375 DOI: 10.1126/science.aaq0049] [Citation(s) in RCA: 384] [Impact Index Per Article: 54.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 10/11/2017] [Indexed: 11/02/2022]
Abstract
On 17 August 2017, gravitational waves (GWs) were detected from a binary neutron star merger, GW170817, along with a coincident short gamma-ray burst, GRB 170817A. An optical transient source, Swope Supernova Survey 17a (SSS17a), was subsequently identified as the counterpart of this event. We present ultraviolet, optical, and infrared light curves of SSS17a extending from 10.9 hours to 18 days postmerger. We constrain the radioactively powered transient resulting from the ejection of neutron-rich material. The fast rise of the light curves, subsequent decay, and rapid color evolution are consistent with multiple ejecta components of differing lanthanide abundance. The late-time light curve indicates that SSS17a produced at least ~0.05 solar masses of heavy elements, demonstrating that neutron star mergers play a role in rapid neutron capture (r-process) nucleosynthesis in the universe.
Collapse
Affiliation(s)
- M R Drout
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.
| | - A L Piro
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - B J Shappee
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.,Institute for Astronomy, University of Hawai'i, 2680 Woodlawn Drive, Honolulu, HI 96822, USA
| | - C D Kilpatrick
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - J D Simon
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - C Contreras
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - D A Coulter
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - R J Foley
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - M R Siebert
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - N Morrell
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - K Boutsia
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - F Di Mille
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - T W-S Holoien
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - D Kasen
- Departments of Physics and Astronomy, 366 LeConte Hall, University of California, Berkeley, CA 94720, USA.,Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - J A Kollmeier
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - B F Madore
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - A J Monson
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.,Department of Astronomy and Astrophysics, The Pennsylvania State University, 525 Davey Laboratory, University Park, PA 16802, USA
| | - A Murguia-Berthier
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - Y-C Pan
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - J X Prochaska
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - E Ramirez-Ruiz
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA.,Dark Cosmology Center, Niels Bohr Institute, University of Copenhagen, Blegdamsvej 17, 2100 Copenhagen, Denmark
| | - A Rest
- Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA.,Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA
| | - C Adams
- Division of Physics, Mathematics, and Astronomy, California Institute of Technology, Pasadena, CA 91125, USA
| | - K Alatalo
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA.,Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA
| | - E Bañados
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - J Baughman
- Massachusetts Institute of Technology, Cambridge, MA, USA.,Núcleo de Astronomía de la Facultad de Ingeniería y Ciencias, Universidad Diego Portales, Avenida Ejército 441, Santiago, Chile
| | - T C Beers
- Department of Physics, University of Notre Dame, Notre Dame, IN 46556, USA.,Joint Institute for Nuclear Astrophysics, Center for the Evolution of the Elements, East Lansing, MI 48824, USA
| | - R A Bernstein
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - T Bitsakis
- Instituto de Radioastronomía y Astrofísica, Universidad Nacional Autónoma de México, C.P. 58190, Morelia, Mexico
| | - A Campillay
- Departamento de Física y Astronomía, Facultad de Ciencias, Universidad de La Serena, Cisternas 1200, La Serena, Chile
| | - T T Hansen
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - C R Higgs
- University of Victoria, Victoria, British Columbia, Canada.,National Research Council Herzberg Institute of Astrophysics, 5071 West Saanich Road, Victoria, British Columbia V9E 2E7, Canada
| | - A P Ji
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - G Maravelias
- Instituto de Física y Astronomía, Universidad de Valparaíso, Avenida Gran Bretaña 1111, Casilla 5030, Valparaíso, Chile
| | - J L Marshall
- George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy, and Department of Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - C Moni Bidin
- Instituto de Astronomía, Universidad Católica del Norte, Avenida Angamos 0610, Antofagasta, Chile
| | - J L Prieto
- Núcleo de Astronomía de la Facultad de Ingeniería y Ciencias, Universidad Diego Portales, Avenida Ejército 441, Santiago, Chile.,Millennium Institute of Astrophysics, Santiago, Chile
| | - K C Rasmussen
- Department of Physics, University of Notre Dame, Notre Dame, IN 46556, USA.,Joint Institute for Nuclear Astrophysics, Center for the Evolution of the Elements, East Lansing, MI 48824, USA
| | - C Rojas-Bravo
- Department of Astronomy and Astrophysics, University of California, Santa Cruz, CA 95064, USA
| | - A L Strom
- The Observatories of the Carnegie Institution for Science, 813 Santa Barbara Street, Pasadena, CA 91101, USA
| | - N Ulloa
- Departamento de Física y Astronomía, Facultad de Ciencias, Universidad de La Serena, Cisternas 1200, La Serena, Chile
| | - J Vargas-González
- Las Campanas Observatory, Carnegie Observatories, Casilla 601, La Serena, Chile
| | - Z Wan
- Sydney Institute for Astronomy, School of Physics, A28, University of Sydney, NSW 2006, Australia
| | - D D Whitten
- Department of Physics, University of Notre Dame, Notre Dame, IN 46556, USA.,Joint Institute for Nuclear Astrophysics, Center for the Evolution of the Elements, East Lansing, MI 48824, USA
| |
Collapse
|
19
|
Alexander MS, Gasperini MJ, Tsai PT, Gibbs DE, Spinazzola JM, Marshall JL, Feyder MJ, Pletcher MT, Chekler ELP, Morris CA, Sahin M, Harms JF, Schmidt CJ, Kleiman RJ, Kunkel LM. Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A. Transl Psychiatry 2016; 6:e901. [PMID: 27676442 PMCID: PMC5048211 DOI: 10.1038/tp.2016.174] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 07/18/2016] [Indexed: 12/31/2022] Open
Abstract
Duchenne muscular dystrophy is caused by mutations in the DYSTROPHIN gene. Although primarily associated with muscle wasting, a significant portion of patients (approximately 25%) are also diagnosed with autism spectrum disorder. We describe social behavioral deficits in dystrophin-deficient mice and present evidence of cerebellar deficits in cGMP production. We demonstrate therapeutic potential for selective inhibitors of the cGMP-specific PDE5A and PDE9A enzymes to restore social behaviors in dystrophin-deficient mice.
Collapse
Affiliation(s)
- M S Alexander
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
- Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, USA
- The Stem Cell Program, Boston Children's Hospital, Boston, MA, USA
| | - M J Gasperini
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
| | - P T Tsai
- The F.M. Kirby Neurobiology Center, Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - D E Gibbs
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
| | - J M Spinazzola
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
- Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, USA
| | - J L Marshall
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
| | - M J Feyder
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
| | - M T Pletcher
- Rare Disease Research Unit, Pfizer, Cambridge, MA, USA
| | - E L P Chekler
- Rare Disease Research Unit, Pfizer, Cambridge, MA, USA
| | - C A Morris
- Rare Disease Research Unit, Pfizer, Cambridge, MA, USA
| | - M Sahin
- The F.M. Kirby Neurobiology Center, Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - J F Harms
- Neuroscience Research Unit, Pfizer Global Research and Development, Cambridge, MA, USA
| | - C J Schmidt
- Neuroscience Research Unit, Pfizer Global Research and Development, Cambridge, MA, USA
| | - R J Kleiman
- The F.M. Kirby Neurobiology Center, Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - L M Kunkel
- Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA
- Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, USA
- The Stem Cell Program, Boston Children's Hospital, Boston, MA, USA
- The Manton Center for Orphan Diseases, Boston, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
| |
Collapse
|
20
|
Marshall JL, Falconer J, Kapoor S, Filer A, Raza K, Young SP, Buckley CD. A3.04 Stromal cell metabolism; the reverse warburg effect in the inflamed synovium. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Dunne EM, Marshall JL, Baker CA, Manning J, Gonis G, Danchin MH, Smeesters PR, Satzke C, Steer AC. Detection of group a streptococcal pharyngitis by quantitative PCR. BMC Infect Dis 2013; 13:312. [PMID: 23844865 PMCID: PMC3711935 DOI: 10.1186/1471-2334-13-312] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2013] [Accepted: 06/25/2013] [Indexed: 11/30/2022] Open
Abstract
Background Group A streptococcus (GAS) is the most common bacterial cause of sore throat. School-age children bear the highest burden of GAS pharyngitis. Accurate diagnosis is difficult: the majority of sore throats are viral in origin, culture-based identification of GAS requires 24–48 hours, and up to 15% of children are asymptomatic throat carriers of GAS. The aim of this study was to develop a quantitative polymerase chain reaction (qPCR) assay for detecting GAS pharyngitis and assess its suitability for clinical diagnosis. Methods Pharyngeal swabs were collected from children aged 3–18 years (n = 91) and adults (n = 36) located in the Melbourne area who presented with sore throat. Six candidate PCR assays were screened using a panel of reference isolates, and two of these assays, targeting speB and spy1258, were developed into qPCR assays. The qPCR assays were compared to standard culture-based methods for their ability to detect GAS pharyngitis. GAS isolates from culture positive swabs underwent emm-typing. Clinical data were used to calculate McIsaac scores as an indicator of disease severity. Results Twenty-four of the 127 samples (18.9%) were culture-positive for GAS, and all were in children (26%). The speB qPCR had 100% sensitivity and 100% specificity compared with gold-standard culture, whereas the spy1258 qPCR had 87% sensitivity and 100% specificity. Nine different emm types were found, of which emm 89, 3, and 28 were most common. Bacterial load as measured by qPCR correlated with culture load. There were no associations between symptom severity as indicated by McIsaac scores and GAS bacterial load. Conclusions The speB qPCR displayed high sensitivity and specificity and may be a useful tool for GAS pharyngitis diagnosis and research.
Collapse
Affiliation(s)
- Eileen M Dunne
- Pneumococcal Research, Murdoch Childrens Research Institute, Parkville, VIC, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013; 24:1574-9. [PMID: 23429865 DOI: 10.1093/annonc/mdt019] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Cardiovascular risk attributable to bevacizumab (Avastin(®), BEV) for treatment of metastatic colorectal cancer (CRC) remains unclear. We conducted a population-based cohort study to assess the safety of BEV use among patients aged ≥ 65. PATIENTS AND METHODS We identified CRC patients diagnosed from 2005 to 2007 who received chemotherapy and were followed until 31 December 2009. Outcomes were 3-year risk of arterial thromboembolic events (ATEs), cardiomyopathy or congestive heart failure (CM/CHF), and cardiac death (CD) after chemotherapy initiation. We fitted Cox-proportional hazards (PHs) models with inverse-probability-of-treatment-weights and calculated hazard ratios (HRs) for the risk of adverse events. RESULTS We identified 6803 CRC patients (median age: 73 years). Those with cardiac comorbidity were less likely to receive BEV (P < 0.0001). BEV is associated with an elevated risk of ATEs (HR = 1.82, 95% CI = 1.20-2.76, P < 0.001; rate difference: 3.5 additional cases/1000 person-years). We observed no association between BEV and CD or CM/CHF. CONCLUSIONS In general practice, the cardiovascular risk of BEV in elderly CRC is modest. The observed ATEs risk is lower than reported in clinical trials, which may be due to careful patient selection. Our findings may facilitate clinical decision-making of BEV use in elderly patients.
Collapse
Affiliation(s)
- H-T Tsai
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20007-2401, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009; 28:961-72. [PMID: 19137011 DOI: 10.1038/onc.2008.448] [Citation(s) in RCA: 184] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with few effective therapeutic options for advanced disease. At least 40% of HCCs are clonal, potentially arising from STAT3+, NANOG+ and OCT3/4+ liver progenitor/stem cell transformation, along with inactivation of transforming growth factor-beta (TGF-beta) signaling. Here we report significantly greater signal transducer and activator of transcription 3 (STAT3) and tyrosine phosphorylated STAT3 in human HCC tissues (P<0.0030 and P<0.0455, respectively) than in human normal liver. Further, in HCC cells with loss of response to TGF-beta, NSC 74859, a STAT3-specific inhibitor, markedly suppresses growth. In contrast, CD133(+) status did not affect the response to STAT3 inhibition: both CD133(+) Huh-7 cells and CD133(-) Huh-7 cells are equally sensitive to NSC 74859 treatment and STAT3 inhibition, with an IC(50) of 100 muM. Thus, the TGF-beta/beta2 spectrin (beta2SP) pathway may reflect a more functional 'stem/progenitor' state than CD133. Furthermore, NSC 74859 treatment of Huh-7 xenografts in nude mice significantly retarded tumor growth, with an effective dose of only 5 mg/kg. Moreover, NSC 74859 inhibited tyrosine phosphorylation of STAT3 in HCC cells in vivo. We conclude that inhibiting interleukin 6 (IL6)/STAT3 in HCCs with inactivation of the TGF-beta/beta2SP pathway is an effective approach in management of HCCs. Thus, IL6/STAT3, a major signaling pathway in HCC stem cell renewal and proliferation, can provide a novel approach to the treatment of specific HCCs.
Collapse
Affiliation(s)
- L Lin
- Cancer Genetics, Digestive Diseases, and Developmental Molecular Biology, Department of Surgery, Georgetown University, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Maternally inherited endosymbionts have been implicated as significant drivers of sexual conflict within their hosts, typically through sex-ratio manipulation. Empirical studies show that some of these endosymbionts have the potential to influence sexual conflict not by sex-ratio distortion, but by altering reproductive traits within their hosts. Research has already shown that reproductive traits involved in mating/fertilization process are integral 'players' in sexual conflict, thus suggesting the novel hypothesis that endosymbiont-induced changes in reproductive phenotypes can impact the dynamics of sexual conflict. Here, we use a standard quantitative genetic approach to model the effects of endosymbiont-induced changes in a female reproductive trait on the dynamics of sexual conflict over mating/fertilization rate. Our model shows that an endosymbiont-induced alteration of a host female reproductive trait that affects mating rate can maintain the endosymbiont infection within the host population, and does so in the absence of sex-ratio distortion and cytoplasmic incompatibility.
Collapse
Affiliation(s)
- T I Hayashi
- Department of Ecology and Evolutionary Biology, University of Tennessee, Knoxville, TN, USA.
| | | | | |
Collapse
|
25
|
Liu MC, Marshall JL, Pestell RG. Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation. Curr Cancer Drug Targets 2004; 4:403-24. [PMID: 15320717 DOI: 10.2174/1568009043332907] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Tumor development, growth, and progression depend on some combination of altered cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Understanding the complex molecular mechanisms that underlie these processes should therefore lead to the identification of potential targets for therapeutic intervention. The estrogen receptor and HER-2/neu were among the earliest targets investigated, ultimately leading to the widespread use of tamoxifen and trastuzumab, respectively, in the treatment of breast cancer. Major research advances have since led to other classes of targeted therapies, including cyclin-dependent kinase inhibitors, histone deactylase inhibitors, and receptor tyrosine kinase inhibitors. The following review provides a discussion of the molecular biology associated with each of these types of therapies as well as a detailed summary of the preclinical and clinical data published on selected compounds from each of these subgroups.
Collapse
Affiliation(s)
- M C Liu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd. NW, Washington, DC 20007, USA.
| | | | | |
Collapse
|
26
|
Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90:1190-7. [PMID: 15026800 PMCID: PMC2409640 DOI: 10.1038/sj.bjc.6601676] [Citation(s) in RCA: 276] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies. A total of 1207 patients with previously untreated mCRC were randomised to either oral capecitabine (1250 mg m−2 twice daily, days 1−14 every 21 days; n=603) or intravenous (i.v.) bolus 5-fluorouracil/leucovorin (5-FU/LV; Mayo Clinic regimen; n=604). Capecitabine demonstrated a statistically significant superior response rate compared with 5-FU/LV (26 vs 17%; P<0.0002). Subgroup analysis demonstrated that capecitabine consistently resulted in superior response rates (P<0.05), even in patient subgroups with poor prognostic indicators. The median time to response and duration of response were similar and time to progression (TTP) was equivalent in the two arms (hazard ratio (HR) 0.997, 95% confidence interval (CI) 0.885–1.123, P=0.95; median 4.6 vs 4.7 months with capecitabine and 5-FU/LV, respectively). Multivariate Cox regression analysis identified younger age, liver metastases, multiple metastases and poor Karnofsky Performance Status as independent prognostic indicators for poor TTP. Overall survival was equivalent in the two arms (HR 0.95, 95% CI 0.84–1.06, P=0.48; median 12.9 vs 12.8 months, respectively). Capecitabine results in superior response rate, equivalent TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for MCRC. For patients in whom fluoropyrimidine monotherapy is indicated, capecitabine should be strongly considered. Following encouraging results from phase I and II trials, randomised trials are evaluating capecitabine in combination with irinotecan, oxaliplatin and radiotherapy. Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy.
Collapse
Affiliation(s)
- E Van Cutsem
- University Hospital Gasthuisberg, Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 2001; 7:3912-9. [PMID: 11751482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
PURPOSE A Phase I study of squalamine, a novel antiangiogenic agent originally isolated from the dogfish shark Squalus acanthias, was conducted in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of squalamine lactate when given as a 120-h continuous i.v. infusion every two weeks; and (b) to obtain information on prolonged (>120-h) continuous i.v. infusions in patients who have tolerated 120-h infusions. EXPERIMENTAL DESIGN A rapid dose escalation scheme was used that permitted intrapatient dose escalation. Three or more patients were treated at each dose, of which at least one patient started treatment de novo at that dose. Once DLT was encountered, the dose was decreased by one dose level, and the duration of infusion was prolonged from 10 up to 30 days in 5-day increments. RESULTS Nineteen patients were treated at eight squalamine dose levels; the number of patients/dose level who received 120-h infusions were [expressed as dose in mg/m(2)/day (number of patients initiated de novo at that dose/total number of patients treated at that dose)]: 6 (3/3), 12 (3/6), 24 (1/5), 48 (2/6), 96 (4/10), 192 (2/6), 384 (3/8), and 538 (1/5). DLT was encountered at 384 mg/m(2)/day (1/3 de novo patients, 5/8 total patients) and 538 mg/m(2)/day (1/1 de novo patients, 4/5 total patients) and consisted of hepatotoxicity, characterized by grade 3 transaminase elevations that resolved 3-11 days after ceasing squalamine infusion. Three patients did not experience hepatotoxicity when first treated at 384 mg/m(2)/day but developed DLT at the same dose when de-escalated from 538 mg/m(2)/day. Other toxicities included grade 1-3 fatigue, grade 1-2 nausea, anorexia, and neuromuscular symptoms. The maximum duration of continuous i.v. infusion was 20 days at a dose rate of 192 mg/m(2)/day in one patient without adverse effects. Pharmacokinetic calculations revealed a linear relationship between area under the curve or Cmax and squalamine dose rate up to 384 mg/m(2)/day, with a prolonged terminal squalamine persistence in patient plasma (median t(1/2) = 18 h; range, 8-48 h). Transient tumor responses were observed in a patient with synovial cell sarcoma and a patient with breast carcinoma with cutaneous metastases. CONCLUSIONS The best tolerated dose rate of squalamine when administered as a 120-h continuous i.v. infusion was 192 mg/m(2)/day; however, patients without prior exposure to squalamine appeared to tolerate a dose rate of 384 mg/m(2)/day without DLT. On the basis of preclinical evidence of synergy with cytotoxic agents and demonstration of human safety from this trial, additional clinical trials have been initiated with squalamine in combination with chemotherapy for patients with late stage lung cancer and ovarian cancer.
Collapse
Affiliation(s)
- P Bhargava
- Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Marshall JL, Mead P, Jones K, Kaba E, Roberts AP. The implementation of venous leg ulcer guidelines: process analysis of the intervention used in a multi-centre, pragmatic, randomized, controlled trial. J Clin Nurs 2001; 10:758-66. [PMID: 11822847 DOI: 10.1046/j.1365-2702.2001.00540.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The production and implementation of clinical practice guidelines is currently a high political priority and a rapidly developing field within healthcare in the United Kingdom (UK). Their purpose is to provide clinicians with a synthesis of the best available external evidence and operationalize the implementation of evidence-based practice. Despite indications that clinical guidelines can make a difference to the quality of patient care, there is some evidence that practitioners struggle with their application. The aim of this paper is to report one element of a trial undertaken by three collaborating universities in the Northern and Yorkshire Region of the UK health service during 1997-1998. The objective was to understand what makes guidelines acceptable and usable, or otherwise, to health professionals. The findings reported in this paper describe the process of care in those general practices that elected to implement guidelines for the management of patients with venous leg ulcers. We conclude that planning for training, resource and quality improvement processes must be built into a team's guidelines implementation procedures. A preliminary needs analysis of the contextual 'hurdles and levers' within each primary healthcare team is also necessary to identify individual issues that must be addressed if the process is to succeed. These findings provide some lessons for successful implementation of clinical guidelines in general. Recommendations for nursing policy makers, managers, practitioners and researchers are included.
Collapse
Affiliation(s)
- J L Marshall
- Centre for Research in Primary Care, University of Leeds, UK.
| | | | | | | | | |
Collapse
|
29
|
Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 2001; 48:95-103. [PMID: 11561784 DOI: 10.1007/s002800100317] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and effect of drug sequence on toxicities and pharmacokinetics of the combination of gemcitabine and docetaxel. METHODS A total of 34 patients with advanced cancers were treated with gemcitabine and docetaxel on days 1 and 8 of each 21-day cycle according to the following dose escalation schedule: level 1, 800 and 30 mg/m2, respectively; level 2, 800 and 40 mg/m2; level 3, 1,000 and 40 mg/m2; and level 4, 1,250 and 40 mg/m2. At each dose level, at least three patients were assigned to one of the two sequences of drug administration: gemcitabine-->docetaxel or docetaxel-->gemcitabine. Once the MTD had been reached, six additional patients, who had received no more than one chemotherapy regimen, were enrolled to dose levels 3 and 4 (gemcitabine-->docetaxel) to determine the MTD in minimally pretreated patients. RESULTS Neutropenia was the most frequent DLT with an overall incidence of 23.5%. Grade 3/4 neutropenia occurred in 62% of patients (8/13) who had received two or more prior chemotherapy regimens, but not at all (0/15) in patients who had received no more than one prior chemotherapy regimens (P< 0.001). Additional DLTs included grade 4 diarrhea and grade 4 stomatitis in one patient each. The MTD was determined to be gemcitabine 800 mg/m2 and docetaxel 40 mg/m2 in patients who had received two or more prior chemotherapy regimens. However, minimally pretreated patients (no more than one prior chemotherapy regimen) were able to tolerate higher doses with an MTD of gemcitabine 1,250 mg/m2 and docetaxel 40 mg/m2. There were no significant differences in toxicities or pharmacokinetics between the two sequences of administration. Partial and minor responses were observed in 23.5% of patients: non-small-cell lung (two of eight), gastric (two of three), head and neck (one of two), bladder (two of four) and hepatocellular cancer (one of one). CONCLUSIONS The combination of gemcitabine and docetaxel administered on days 1 and 8 every 21 days was feasible and well tolerated in patients with advanced malignancies. The sequence of administration had no significant effect on the toxicity or pharmacokinetics of either drug. Minimally pretreated patients tolerated higher doses of this combination without significant toxicities. This schedule and combination demonstrated activity in a variety of solid tumors, and merits further evaluation.
Collapse
Affiliation(s)
- P Bhargava
- Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- D J Howard
- Department of Biology, New Mexico State University, Las Cruces, NM 88003, USA.
| | | | | | | |
Collapse
|
31
|
Bansal R, Chen HX, Marshall JL, Tan J, Glazer RI, Wainer IW. Detection of a mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis. J Chromatogr B Biomed Sci Appl 2001; 750:129-35. [PMID: 11204212 DOI: 10.1016/s0378-4347(00)00436-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A simple, rapid and sensitive method has been developed and validated for the analysis of a mixed-backbone oligonucleotide (GEM 231) in tumor tissues. The analysis was performed using a capillary electrophoresis (CE) system with UV detection. An extended light path (bubble cell) capillary column of 64.5 cm (effective length 56 cm) x 50 microm I.D. is used as the separation column. The optimized chromatographic conditions were background electrolyte: sodium borate buffer (60 mM, pH 9.1), electrokinetic injection: 10 s, applied voltage: 30 kV, detection at lambda = 210 nm. A linear relationship was observed between the peak area and the amount of GEM 231 in the range of 1.0-1000 microg/ml. The lower detection limit of the drug was 100 pg with an average recovery of about 75 +/- 5%. The inter-day and intra-day relative standard deviations were <10%. Assay validation studies revealed that CE method is reproducible and specific for the determination of GEM 231 in tissue homogenates with a run time of less than 5 min.
Collapse
Affiliation(s)
- R Bansal
- Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, USA
| | | | | | | | | | | |
Collapse
|
32
|
Marshall JL. Capecitabine in colorectal cancer. Oncology (Williston Park) 2001; 15:41-6; discussion 46-7. [PMID: 11219977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Capecitabine (Xeloda) is the first orally available fluoropyrimidine approved for use in patients with cancer. It was initially approved for use in metastatic breast cancer, but significant data also support its use in the management of metastatic colorectal cancer. Capecitabine relies on a series of metabolic steps, the last of which occurs primarily within cancer cells. This results in selective activation of the compound within cancer cells, thereby reducing systemic toxicities and allowing for greater dose intensity. This article reviews selected phase I, phase II, and phase III clinical trials conducted in patients with colorectal cancer that document the metabolic activation of this compound and support its use in patients with advanced colorectal cancer.
Collapse
Affiliation(s)
- J L Marshall
- Lombardi Cancer Center, Georgetown University, Washington, DC, USA
| |
Collapse
|
33
|
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964-73. [PMID: 11099326 DOI: 10.1200/jco.2000.18.23.3964] [Citation(s) in RCA: 224] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen. PATIENTS AND METHODS Eighteen patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receive either recombinant vaccinia (rV)-CEA followed by three avipox-CEA vaccinations, or avipox-CEA (three times) followed by one rV-CEA vaccination. Subsequent vaccinations in both cohorts were with avipox-CEA. Immunologic monitoring was performed using a CEA peptide and the enzyme-linked immunospot assay for interferon gamma production. RESULTS rV-CEA followed by avipox-CEA was superior to the reverse order in the generation of CEA-specific T-cell responses. Further increases in CEA-specific T-cell precursors were seen when local granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin (IL)-2 were given with subsequent vaccinations. The treatment was extremely well tolerated. Limited clinical activity was seen using vaccines alone in this patient population. Antibody production against CEA was also observed in some of the treated patients. CONCLUSION rV-CEA was more effective in its role as a primer of the immune system; avipox-CEA could be given up to eight times with continued increases in CEA T-cell precursors. Future trials should use rV-CEA first followed by avipox-CEA. Vaccines specific to CEA are able to generate CEA-specific T-cell responses in patients without significant toxicity. T-cell responses using vaccines alone may be inadequate to generate significant anticancer objective responses in patients with advanced disease. Cytokines such as GM-CSF and IL-2 may play a key role in generating such responses.
Collapse
Affiliation(s)
- J L Marshall
- Georgetown University Medical Center, Vincent T. Lombardi Cancer Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000; 49:517-29. [PMID: 11129322 PMCID: PMC11037011 DOI: 10.1007/s002620000145] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
An enzyme-linked immunosorbent spot (ELISPOT) assay for interferon gamma production has been used to analyze specific T cell responses to a Flu 9-mer peptide, and a 9-mer peptide of carcinoembryonic antigen (CEA). Assays were performed on peripheral blood mononuclear cells (PBMC) of HLA-A2-positive patients with CEA-expressing carcinomas, both before and after vaccination with CEA-based vaccines, and from HLA-A2-positive healthy blood donors. The ELISPOT assay utilized aliquots of frozen PBMC, and assays were performed after 24 h in culture with peptide to rule out any artifacts due to long-term in vitro stimulation cycles. An internal standard was used for each assay to define reproducibility of the assay, and all samples from a given patient (pre- and post-vaccination, with both the Flu and CEA peptides) were analyzed simultaneously. The results indicated a trend towards healthy blood donors having higher levels of Flu-specific T cell precursors than do colon carcinoma patients, but these results were not statistically significant (P = 0.06). On the other hand, slightly higher CEA-specific T cell responses were observed in cancer patients with CEA-expressing carcinomas than in healthy blood donors. PBMC from two CEA-based vaccine clinical trials were analyzed for T cell responses to the same CEA peptide and to the Flu control peptide. The first trial consisted of three monthly vaccinations of CEA peptide (designated PPP) in adjuvant. The second trial consisted of cohorts receiving three monthly vaccinations of avipox-CEA recombinant (designated AAA) or cohorts receiving a primary vaccination with recombinant vaccinia-CEA followed by two monthly vaccinations with avipox-CEA (designated VAA). Few, if any, CEA-specific T cell responses were seen in the PPP vaccinations, while the majority of patients receiving the poxvirus CEA recombinants demonstrated increases in CEA-specific T cell responses and no increases in Flu-specific responses. CEA-specific IgG responses were also demonstrated in patients following recombinant CEA poxvirus vaccinations. Statistical analyses of the T cell responses to the same CEA peptide demonstrated a P value of 0.028 for the recombinant poxvirus vaccines, as compared with the peptide vaccine. There were no differences seen (P = 0.37) in Flu-specific responses after these two types of CEA vaccination. These results thus provide the first evidence that poxvirus recombinant-based vaccines are more potent in the initiation of tumor-antigen-specific T cell responses than vaccines employing peptide in adjuvant, when assays are conducted in an identical manner, and in defining responses to the same peptide. These results also demonstrate for the first time that an ELISPOT assay, performed over a 24-h period and without in vitro sensitization, can be successfully used to monitor immune responses to a tumor-associated antigen in cancer patients.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Antibodies, Neoplasm/biosynthesis
- Antibodies, Viral/biosynthesis
- Antigen-Presenting Cells/immunology
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- Avipoxvirus/immunology
- Blood Donors
- Breast Neoplasms/immunology
- Breast Neoplasms/therapy
- Cancer Vaccines/immunology
- Cancer Vaccines/therapeutic use
- Carcinoembryonic Antigen/genetics
- Carcinoembryonic Antigen/immunology
- Carcinoma/immunology
- Carcinoma/therapy
- Cell Line
- Cohort Studies
- Cytotoxicity, Immunologic
- Digestive System Neoplasms/immunology
- Digestive System Neoplasms/therapy
- Enzyme-Linked Immunosorbent Assay
- Genes, Synthetic
- HLA-A2 Antigen/analysis
- Humans
- Immunoglobulin G/biosynthesis
- Immunotherapy, Active
- Interferon-gamma/analysis
- Interferon-gamma/biosynthesis
- Lung Neoplasms/immunology
- Lung Neoplasms/therapy
- Lymphocyte Activation
- Peptide Fragments/genetics
- Peptide Fragments/immunology
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/therapeutic use
- Viral Vaccines/immunology
- Viral Vaccines/therapeutic use
Collapse
Affiliation(s)
- P Arlen
- Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 2000; 49:485-8. [PMID: 10792207 PMCID: PMC2014949 DOI: 10.1046/j.1365-2125.2000.00189.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AIMS To examine the relationship between cytochrome P450 2C19 (CYP2C19) genotype and expressed metabolic activity in 16 patients with advanced metastatic cancer. METHODS Individual CYP2C19 genotypes were determined by PCR-based amplification, followed by restriction fragment length analysis, and compared with observed CYP2C19 metabolic activity, as determined using the log hydroxylation index of omeprazole. RESULTS All 16 patients had an extensive metabolizer genotype. However, based on the antimode in a distribution of log omeprazole hydroxylation indices from healthy volunteers, four of the patients had a poor metabolizer phenotype and there was a general shift of the remaining 12 patients towards a slower metabolic phenotype. This suggests a reduction in metabolic activity for all patients relative to healthy volunteers. A careful analysis of patient medical records failed to reveal any drug interactions or other source for the observed discordance between genotype and phenotype. CONCLUSIONS There are no previous reports of a 'discordance' between genotype and expressed enzyme activity in cancer patients. Such a decrease in enzyme activity could have an impact on the efficacy and toxicity of chemotherapeutic agents and other drugs, used in standard oncology practice.
Collapse
Affiliation(s)
- M L Williams
- Department of Pharmacology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington, D.C., 20007, USA
| | | | | | | | | | | |
Collapse
|
36
|
Marshall JL, Baidas S, Bhargava P, Rizvi N. Matrix metalloproteinase inhibitors in cancer: an update. IDrugs 2000; 3:518-24. [PMID: 16100684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Affiliation(s)
- J L Marshall
- Lombardi Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007, USA.
| | | | | | | |
Collapse
|
37
|
Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 2000; 6:1259-66. [PMID: 10778949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an important role in growth and maintenance of malignancies. Preclinically, GEM231 inhibited human cancer xenografts either alone or synergistically with chemotherapeutic agents and has demonstrated an improved metabolic stability and safety profile compared to the first-generation compounds. Objectives of this study were to define the safety profile and pharmacokinetics of GEM231 administered as 2-h IV infusions twice weekly in patients with refractory solid tumors. Fourteen patients (13 evaluable for safety) received escalating doses of GEM231 at 20-360 mg/m2 (2.5-9 mg/kg). Tumor histologies included non-small cell lung cancer, renal cell cancer, sarcoma, and others. The plasma pharmacokinetics of GEM231 were linear and predictable. Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2. The plasma half-life was about 1.5 h. The only clinical toxicities were transient grade I-II fever and fatigue at doses > or = 240 mg/m2. There was no treatment-related complement activation or thrombocytopenia at any dose level, except with the first dose in one patient who had pre-existing borderline thrombocytopenia. Transient activated partial thrombin time prolongation occurred at doses > or =160 mg/m2. Dose-limiting toxicities included transient activated partial thrombin time prolongation (one of three patients at 360 mg/m2) and cumulative reversible transaminase elevation (three of three patients at 360 mg/m2 and three of six patients at 240 mg/m2 during weeks 3-10). One patient with colon cancer had stabilization of a previously rising carcinoembryonic antigen. Thus, in this first clinical evaluation of a mixed-backbone oligonucleotide in cancer patients, high plasma concentrations of GEM231 were well tolerated without significant acute toxicities, but prolonged treatment was associated with reversible transaminitis. Although 240 mg/m2 by 2-h infusion twice weekly was safe for a 4-week treatment duration, alternative dosing schedules are being tested to minimize the cumulative toxicity, which will be essential to extend the duration of therapy at the highest GEM231 dose tested.
Collapse
MESH Headings
- Aged
- Alanine Transaminase/blood
- Alanine Transaminase/drug effects
- Area Under Curve
- Base Sequence
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/metabolism
- Carcinoma, Renal Cell/drug therapy
- Carcinoma, Renal Cell/metabolism
- Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
- Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
- Cyclic AMP-Dependent Protein Kinases/genetics
- Diarrhea/chemically induced
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Fatigue/chemically induced
- Female
- Fever/chemically induced
- Humans
- Infusions, Intravenous
- Kidney Neoplasms/drug therapy
- Kidney Neoplasms/metabolism
- Lung Neoplasms/drug therapy
- Lung Neoplasms/metabolism
- Male
- Metabolic Clearance Rate
- Middle Aged
- Neoplasms/drug therapy
- Neoplasms/metabolism
- Oligonucleotides, Antisense/adverse effects
- Oligonucleotides, Antisense/chemistry
- Oligonucleotides, Antisense/pharmacokinetics
- Partial Thromboplastin Time
- Sarcoma/drug therapy
- Sarcoma/metabolism
- Time Factors
- Treatment Outcome
Collapse
Affiliation(s)
- H X Chen
- Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Warner RR, Boissy YL, Lilly NA, Spears MJ, McKillop K, Marshall JL, Stone KJ. Water disrupts stratum corneum lipid lamellae: damage is similar to surfactants. J Invest Dermatol 1999; 113:960-6. [PMID: 10594737 DOI: 10.1046/j.1523-1747.1999.00774.x] [Citation(s) in RCA: 138] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Using electron microscopy, we investigated the effect of (i) a dilute surfactant and of water alone on the ultrastructure of stratum corneum lipids in pig skin exposed in vitro at 46 degrees C, and (ii) of water alone on human skin exposed in vivo at ambient temperature. For pig skin, the surfactant sodium dodecyl sulfate disrupts stratum corneum intercellular lamellar bilayers, leading to bilayer delamination and "roll-up" in a water milieu after 1 h, extensive bilayer disruption after 6 h, and nearly complete dissociation of corneocytes after 24 h. Corneodesmosomes show progressive degradation with exposure time. Water alone also disrupts the stratum corneum, but with a slower onset. Alterations in intercellular lamellar bilayers, but not intercellular lamellar bilayer roll-up, are detected after 2 h. Intercellular lamellar bilayer roll-up occurs after 6 h. Extensive dissociation of corneocytes occurs after 24 h of water exposure. Unlike sodium dodecyl sulfate, water exposure results in the formation of amorphous intercellular lipid. Corneodesmosome degradation parallels intercellular lamellar bilayer disruption; calcium appears to offer some protection. Similar disruption of intercellular lamellar bilayers occurs in human skin in vivo at ambient temperature. Our studies show that water can directly disrupt the barrier lipids and are consistent with surfactant-induced intercellular lamellar bilayer disruption being due at least in part to the deleterious action of water. Intercellular lamellar bilayer disruption by water would be expected to enhance permeability and susceptibility to irritants; accordingly, increased attention should be given to the potential dangers of prolonged water contact. For common in vitro procedures, such as skin permeation studies or isolation of stratum corneum sheets, exposure to water should also be minimized.
Collapse
Affiliation(s)
- R R Warner
- Miami Valley Laboratories, Procter & Gamble, Cincinnati 452539, USA.
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
1. An investigation was performed in pentobarbitone anaesthetized rats to compare the renal vasoconstrictor actions of endothelin-1 (ET-1), endothelin-3 (ET-3) and sarafotoxin 6c and their dependency on NO production. 2. Intra-renal arterial infusion of ET-1 and ET-3, from 1 - 1000 ng had no effect on blood pressure, but reduced renal blood flow maximally by 82 and 81% with EC50 values of 510+/-18 and 1113+/-17 ng, respectively and correspondingly increased renal vascular resistance and decreased conductance. 3. Direct renal arterial administration of sarafotoxin 6c was without effect on blood pressure but caused a maximum reduction in renal blood flow of 56% at 300 ng and had an EC50 of 86+/-4 ng. 4. Administration of the selective ETA receptor antagonist FR139317 at 0.3 and 1.0 mg kg-1 had no effect on basal levels of blood pressure, renal vascular resistance or renal blood flow. The lower dose of FR139317 had no effect on the ET-1 dose-response curve for renal blood flow while at 1.0 mg kg-1, FR139317 reduced the EC50 to 363+/-32 ng (P<0.05). 5. Infusion of L-NAME, 10 microg kg-1 min-1 increased blood pressure by approximately 15%, increased renal vascular resistance and decreased renal blood flow by some 40%. The EC50 values for renal blood flow were reduced to 358+/-68 ng (P<0.05) for ET-1, 638+/-69 ng (P<0.05) for ET-3 and 55+/-10 ng (P<0.01) for sarafotoxin 6c. The maximal reduction in renal blood flow induced by sarafotoxin 6c was raised (P<0.01) from 56% to approximately 100% and renal vascular resistance increased when NO production was blocked. 6. These results showed that the vasoconstrictor actions of ET-1 and ET-3 on resistance vessels controlling renal blood flow are mediated via ETB rather than ETA receptors. Moreover, both ET-1 and ET-3 dependent vasoconstrictions are slightly attenuated by concomitant NO production. By contrast, sarafotoxin 6c appears much more potent at the renal resistance vasculature and is much more powerfully modulated by NO.
Collapse
Affiliation(s)
- J L Marshall
- Department of Physiology, The Medical School, Birmingham B15 2TT
| | | |
Collapse
|
40
|
Rizvi NA, Spiridonidis CH, Davis TH, Bhargava P, Marshall JL, Dahut W, Figuera M, Hawkins MJ. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol 1999; 26:27-31; discussion 41-2. [PMID: 10585006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Docetaxel and gemcitabine have been shown to be active as single agents in a variety of solid tumors. These two agents have been studied in combination with several different treatment schedules. Two phase I studies used a novel 2-week administration schedule that involved a 1-hour infusion of 35 mg/m2 to 65 mg/m2 docetaxel and gemcitabine administered as either a 30-minute infusion (2,000 to 4,000 mg/m2) or a 10 mg/m2/min infusion (1,000 to 1,200 mg/m2 total dose). Another novel phase I study evaluated the effect of drug sequence on toxicities. Patients received 30 to 40 mg/m2 docetaxel and 800 to 1,250 mg/m2 gemcitabine on days 1 and 8 every 21 days. Two phase I studies of a monthly docetaxel regimen have been conducted. Patients received 800 mg/m2 gemcitabine on days 1, 8, and 15 and 100 mg/m2 docetaxel on day 1 of a 28-day cycle. Finally, in a phase II study, patients received 900 mg/m2 gemcitabine on days 1 and 8 and 100 mg/m2 docetaxel on day 8, with granulocyte colony-stimulating factor administered on days 9 through 15. In these studies, antitumor responses were observed in lung cancer as well as a number of other histologies. Neutropenia was the most frequent dose-limiting toxicity and no difference in clinical toxicity was observed with either sequence of administration. The emerging evidence suggests, therefore, that the combination of gemcitabine and docetaxel is active in a variety of solid tumors and is well tolerated.
Collapse
Affiliation(s)
- N A Rizvi
- Department of Medicine, Lombardi Cancer Center, Washington, DC, USA
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5:1989-95. [PMID: 10473076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
A Phase I study of angiogenesis inhibitor TNP-470 was conducted in patients with advanced cancer. TNP-470 (25-235 mg/m2) was administered i.v. over 4 h once a week to patients who had solid tumors refractory to the best available treatment or with a high risk of recurrence and who had normal renal, hepatic, and hematological function and no evidence of coagulopathy. The aims of the study were to determine the maximum tolerated dose, dose-limiting toxicities (DLTs), and the pharmacokinetics of TNP-470 given on a once-weekly schedule. Thirty-six patients, ages 23-75 (median, 54 years), with an Eastern Cooperative Oncology Group performance status of 0-2 were treated. The number of patients at each dose level (mg/m2) were 6 (25), 3 (50), 3 (75), 3 (100), 3 (133), 12 (177), and 6 (235). The principal toxicities of TNP-470 were dizziness, lightheadedness, vertigo, ataxia, decrease in concentration and short-term memory, confusion, anxiety, and depression, which occurred at doses of 133, 177, and 235 mg/m2. Two patients treated at 235 mg/m2 experienced DLT in the form of grade III cerebellar neurotoxicity after 6 weeks of treatment. Overall, these neurological symptoms were dose-related, had an insidious onset, progressively worsened with treatment, and resolved completely within 2 weeks of stopping the drug. One patient with malignant melanoma had stabilization of the previously growing disease for 27 weeks while on the treatment. Two patients, one with adenocarcinoma of the colon and the other with a soft tissue sarcoma, had no clinically detectable disease but were at high risk for recurrence at the initiation of treatment and received 13 months and > 3 years of treatment, respectively, with no evidence of disease recurrence. The remaining patients had progression of their disease after 1-6 months of treatment. The mean plasma half-life (t(1/2)) of TNP-470 and its principal metabolite, AGM-1883, were extremely short (harmonic mean, t(1/2) of 2 and 6 min, respectively) with practically no drug detectable in the plasma by 60 min after the end of the infusion. MII, an inactive metabolite, had a considerably longer t(1/2) of approximately 2.6 h. Mean peak TNP-470 concentrations were > or = 400 ng/ml at doses > or = 177 mg/m2. On the basis of this study, the maximum tolerated dose of TNP-470 administered on a weekly schedule was 177 mg/m2 given i.v over 4 h. The principal DLT was neurotoxicity, which appeared to be dose-related and was completely reversible. On the basis of the short plasma t(1/2) of TNP-470, exploration of a prolonged i.v. infusion schedule is warranted.
Collapse
Affiliation(s)
- P Bhargava
- Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 1999; 22:371-9. [PMID: 10404439 DOI: 10.1097/00002371-199907000-00011] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
MDX-H210 is a chemically, cross-linked, half-humanized bispecific antibody composed of F(ab') fragment from monoclonal antibody (mAb) H22 that binds to the high-affinity receptor Fc gamma RI and F(ab') of mAb 520C9 that recognizes the erbB-2 (HER2/neu) oncoprotein. In a previous trial, the murine bispecific, MDX-210 at a dose of 7 mg/m2, was well tolerated and activated monocytes and macrophages in vivo in doses as low as 0.35 mg/m2. In our multidose trial, granulocyte-macrophage colony-stimulating factor, which increases and activates potential effector cells, was given on days 1-4 at 250 micrograms/m2 s.c. and MDX-H210 was given on day 4 weekly for 4 consecutive weeks. Thirteen patients were treated at dose levels of 1, 3.5, 7, 10, 15, and 20 mg/m2 without dose-limiting toxicity. Fever, chills, and rigors occurred during and up to 2 h postinfusion and correlated with the time to peak levels of tumor necrosis factor-alpha (median 88.2 pg/ml; range 15.6-887 pg/ml) and interleukin-6 (median 371 pg/ml; range 175-2,149 pg/ml). By the fourth consecutive week of treatment the side effects and cytokine levels decreased significantly. Human antibispecific antibody (HABA) levels were increased by 200- to 500-fold above pretreatment levels in 5 of 11 evaluable patients after 3 weeks of treatment. The monocyte and granulocyte population increased on days 4 and 11 (median 44%; range 18-68% and 42%; 19-71%), respectively, for monocytes and (60%; 43-75% and 74%; 54-82%) on days 4 and 11 for granulocytes. There was a significant decrease in the monocyte populations immediately after MDX-H210 administration (median decrease 73%; range 42-94%) and (52%; 12-72%) on days 4 and 11, respectively. Ten patients completed 4 weeks of treatment. One patient had a 48% reduction in an index lesions and six patients had stable disease at the time of evaluation. Three patients progressed before the fourth week. The therapy was generally well tolerated with toxicity, primarily, limited to the days of treatment.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/immunology
- Adolescent
- Adult
- Aged
- Antibodies, Bispecific/administration & dosage
- Antibodies, Bispecific/adverse effects
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/blood
- Antibodies, Monoclonal, Humanized
- Antibody Formation/drug effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cytokines/drug effects
- Cytokines/metabolism
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage
- Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects
- Humans
- Injections, Subcutaneous
- Leukocyte Count/drug effects
- Male
- Middle Aged
- Pilot Projects
- Receptor, ErbB-2/blood
- Receptor, ErbB-2/drug effects
- Severity of Illness Index
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- J A Posey
- Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C., USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5:1658-64. [PMID: 10430065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
LGD1069 [Targretin; 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid] is a novel synthetic retinoid X receptor-selective retinoid that has been recently identified. The goals of this study were to determine the safety, toxicity, pharmacokinetics (PKs), and metabolic profile of LGD1069 in advanced cancer patients. Sixty patients received oral LGD1069 at doses ranging from 5-1000 mg/m2/day with PK sampling performed on days 1 and 15. No dose-limiting toxicities (DLTs) were observed up to the 500 mg/m2/day dose level. DLT observed at and above 650 mg/m2/day included skin desquamation, hyperbilirubinemia, transaminase elevation, leukopenia, and diarrhea. Asymptomatic, dose-related alterations in lipid and thyroid metabolism were also observed. DLTs frequently observed with retinoic acid receptor-selective retinoids and pan agonists, including headache, mucocutaneous toxicity, and hypercalcemia, were not dose-limiting with LGD1069. Day 1 LGD1069 Cmax and area under the curve values increased dose-proportionately up to 800 mg/m2/day. Repeat-dose (day 15) area under the curve values varied between 25 and 105% of day 1 values. Although no objective tumor responses were observed, tumor progression may have been substantially arrested or delayed in non-small cell lung cancer (5 of 16) and in head and neck cancer (1 of 5), as well as other tumor types. At the higher dose levels, the molar concentration of LGD1069 was up to 10-fold higher than observed with other retinoids, yet toxicity was minimal. LGD1069 is an retinoid X receptor-selective retinoid agonist with a more favorable PK and toxicity profile than previously studied retinoids and merits further investigation as a chemopreventive and anticancer agent. On the basis of this Phase I trial, the recommended Phase II dose is 500 mg/m2/day.
Collapse
Affiliation(s)
- N A Rizvi
- Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17:332-7. [PMID: 10458251 DOI: 10.1200/jco.1999.17.1.332] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE A phase I clinical trial in patients with advanced carcinoma was conducted, using a replication-defective avipox vaccine containing the gene for the human carcinoembryonic antigen (CEA). The canarypox vector, designated ALVAC, has the ability to infect human cells but cannot replicate. PATIENTS AND METHODS The recombinant vaccine, designated ALVAC-CEA, was administered intramuscularly three times at 28-day intervals. Each cohort of six patients received three doses of either 2.5 x 10(5), 2.5 x 10(6), or 2.5 x 10(7) plaque-forming units of vaccine. RESULTS The vaccine was well tolerated at all dose levels and no significant toxicity was attributed to the treatment. No objective antitumor response was observed during the trial in patients with measurable disease. Studies were conducted to assess whether ALVAC-CEA had the ability to induce cytolytic T-lymphocyte (CTL) responses in patients with advanced cancer. Peripheral blood mononuclear cells (PBMCs) from patients with the MHC class I A2 allele were obtained before vaccine administration and 1 month after the third vaccination. Peripheral blood mononuclear cells were incubated with the CEA immunodominant CTL epitope carcinoembryonic antigen peptide-1 and interleukin 2 and quantitated using CTL precursor frequency analysis. In seven of nine patients evaluated, statistically significant increases in CTL precursors specific for CEA were observed in PBMCs after vaccination, compared with before vaccination. CONCLUSION These studies constitute the first phase I trial of an avipox recombinant in cancer patients. The recombinant vaccine ALVAC-CEA seems to be safe and has been demonstrated to elicit CEA-specific CTL responses. These studies thus form the basis for the further clinical exploration of the ALVAC-CEA recombinant vaccine in phase I/II studies in protocols designed to enhance the generation of human T-cell responses to CEA.
Collapse
Affiliation(s)
- J L Marshall
- Georgetown University Medical Center, Vincent T. Lombardi Cancer Center, Washington, DC 20007, USA
| | | | | | | | | | | | | |
Collapse
|
45
|
Chassaing C, Marshall JL, Wainer IW. Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases. J Chromatogr B Biomed Sci Appl 1998; 719:169-76. [PMID: 9869377 DOI: 10.1016/s0378-4347(98)00387-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A high-performance liquid chromatographic assay has been developed and validated for the determination of the antitumor agent depsipeptide (FR-901228) in plasma samples from patients with advanced cancer. After the plasma proteins were precipitated with acetonitrile, the supernatant was extracted with ethylacetate. Depsipeptide was chromatographed on two serial octadecylsilica stationary phases using a mobile phase consisting of acetonitrile-potassium phosphate buffer (0.03 M, pH 3) (27:73, v/v), at a flow-rate of 2.0 ml/min and at ambient temperature. The method was linear over a 50 to 2000 ng/ml range and the intra- and inter-day coefficients of variations were less than 8%. The method was applied to the determination of the plasma concentration-time profile for 14 patients with advanced cancer receiving from 1 to 7.5 mg/m2 of depsipeptide per day as a continuous 4-h infusion.
Collapse
Affiliation(s)
- C Chassaing
- Georgetown University Bioanalytical Center, Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, USA
| | | | | |
Collapse
|
46
|
Rizvi NA, Marshall JL, Ness E, Yoe J, Gill GM, Truglia JA, Loewen GR, Jaunakais D, Ulm EH, Hawkins MJ. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. Clin Cancer Res 1998; 4:1437-42. [PMID: 9626460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
9-cis-Retinoic acid (9-cis-RA) and all-trans-RA (ATRA) are naturally occurring hormones. The nuclear receptors that mediate the effects of retinoids are the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). ATRA binds RAR with high affinity but does not bind to RXR, whereas 9-cis-RA, an isomer of ATRA, is a ligand that binds and transactivates both RARs and RXRs. The goals of this study were to determine the safety, tolerability, pharmacokinetics, and metabolic profile of 9-cis-RA in advanced cancer patients. Forty-one patients received oral 9-cis-RA (ALRT1057; Panretin capsules) at doses ranging from 5-140 mg/m2/day. Twenty-six patients were treated once daily with up to 140 mg/m2; a subsequent cohort of 15 patients were treated twice daily (b.i.d.) at 100-140 mg/m2/day (50, 60, and 70 mg/m2 b.i.d.) to evaluate a b.i.d. dosing regimen. Headache was the most frequent adverse event and was dose limiting in 3 of 41 patients. Skin toxicity was the next most common toxicity and was seen in 11 of 41 patients; it was typically mild and limited to skin dryness and erythema. Other toxicities included conjunctivitis, flushing, diarrhea, transaminitis, hypercalcemia, and asymptomatic hypertryglyceridemia. Toxicities were typically dose related, occurred primarily above 83 mg/m2/day, and were not ameliorated by b.i.d. dosing. No tumor responses were observed. The mean day 1 area under the plasma concentration-time curve and peak plasma concentration values were dose-proportional over all dose levels, whereas day 15 area under the plasma concentration-time curve and peak plasma concentration values were nonlinear above 83 mg/m2/day, suggesting that 9-cis-RA induced its own metabolism at doses equal to and above 140 mg/m2/day. 9-cis-RA is a retinoid receptor pan agonist with a more favorable pharmacokinetic and toxicity profile than that observed with previously studied retinoids and merits further investigation.
Collapse
Affiliation(s)
- N A Rizvi
- Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C. 20007, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res 1997; 3:2347-54. [PMID: 9815633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Tumor angiogenesis is critically important to tumor growth and metastasis. We have shown that pentosan polysulfate (PPS) is an effective inhibitor of heparin-binding growth factors in vitro and can effectively inhibit the establishment and growth of tumors in nude mice. Following completion of our Phase I trial of s.c. administered PPS, we performed a Phase I trial of p.o. administered PPS in patients with advanced cancer to determine the maximum tolerated dose (MTD) and toxicity profile and to search for any evidence for biological activity in vivo. Patients diagnosed with advanced, incurable malignancies who met standard Phase I criteria and who did not have a history of bleeding complications were enrolled, in cohorts of three, to receive PPS p.o. t.i.d., at planned doses of 180, 270, 400, 600, and 800 mg/m2. Patients were monitored at least every 2 weeks with physical exams and weekly with hematological, chemistry, stool hemoccult, and coagulation blood studies, and serum and urine samples for PPS and basic fibroblastic growth factor (bFGF) levels were also taken. The PPS dose was escalated in an attempt to reach the MTD. Eight additional patients were enrolled at the highest dose to further characterize the toxicity profile and biological in vivo effects of PPS. A total of 21 patients were enrolled in the three cohorts of doses 180 (n = 4), 270 (n = 3), and 400 (n = 14) mg/m2. The most severe toxicities seen were grade 3 proctitis and grade 4 diarrhea; however, 20 of the 21 patients had evidence of grade 1 or 2 gastrointestinal (GI) bleeding. These toxicities became evident at a much earlier time point as the dose was increased, but their severities were similar at all dose levels. There were no objective responses, although three patients had prolonged stabilization of previously progressing disease. Pharmacokinetic analysis suggested marked accumulation of PPS upon chronic administration. Serum and urine bFGF levels failed to show a consistent, interpretable pattern; however the data suggested an inverse relationship between PPS and bFGF levels in vivo. A MTD could not be determined using the daily t.i.d. dosing schedule due to the development of grade 3/4 GI toxicity (proctitis) at all dose levels studied. PPS, administered p.o. at doses of 400 mg/m2 t.i.d., did not cause significant systemic toxicity, but most patients developed moderate-to-severe GI toxicity within 1-2 months. The cause of the GI toxicity was unclear, but it was readily reversible upon cessation of the agent. The suggestion of an inverse relationship between PPS and bFGF supports further study of PPS as an antiangiogenic agent. The tested doses and schedule cannot be recommended for further study. Subsequent murine experiments showed PPS to be more effective as an anticancer agent when it is given intermittently. We propose a study of PPS given on a weekly schedule in further clinical trials.
Collapse
Affiliation(s)
- J L Marshall
- Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Zeman RK, Cooper C, Zeiberg AS, Kladakis A, Silverman PM, Marshall JL, Evans SR, Stahl T, Buras R, Nauta RJ, Sitzmann JV, al-Kawas F. TNM staging of pancreatic carcinoma using helical CT. AJR Am J Roentgenol 1997; 169:459-64. [PMID: 9242754 DOI: 10.2214/ajr.169.2.9242754] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE The purpose of this study was to determine the accuracy of helical CT scanning in predicting the stage of carcinoma of the exocrine pancreas using TNM staging guidelines and in predicting resectability of carcinoma of the exocrine pancreas. MATERIALS AND METHODS Twenty-six patients with proven adenocarcinoma of the pancreas underwent uniphasic or biphasic helical CT scanning. Two observers unaware of the patient's surgical stage evaluated the CT examinations using the TNM system (with specific assessment and description of disease sites). In addition, the two observers rated confidence of nonresectability using a 5-point scale (ranging from 1, definitely resectable, to 5, definitely not resectable). Observer results and preoperative interpretations were compared with surgical findings. RESULTS Nineteen of 26 patients had nonresectable disease. The combined observer scores showed correct determination of T stage in 77% of patients, of N stage in 58%, and of M stage in 79%. The overall accuracy in determining lack of resectability was 96% and 84% for the two observers. All errors in determining resectable versus nonresectable disease occurred when the observer was not maximally confident of his or her diagnosis. CONCLUSION Helical CT is an effective screening technique for assessing T and M stages of pancreatic carcinoma. However, helical CT is poor at detecting regional lymph node involvement. In patients with equivocal T-stage findings (such as questionable venous involvement), other studies such as endoscopic sonography may be of value.
Collapse
Affiliation(s)
- R K Zeman
- Department of Radiology, Georgetown University Medical Center, Washington, DC 20007, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Marshall JL, Richmond E, DeLap RJ. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. Clin Cancer Res 1996; 2:1475-80. [PMID: 9816323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer. Laboratory data suggest that iododeoxyuridine could further enhance the efficacy of leucovorin-fluorouracil regimens. This report describes the Phase I clinical evaluation of a leucovorin-fluorouracil-iododeoxyuridine chemotherapy regimen. Twenty-four patients received treatment with leucovorin (500 mg/m2), fluorouracil (500 mg/m2), and iododeoxyuridine (escalating doses) on days 1 and 8 of a 21-day cycle. The maximum tolerated dose of iododeoxyuridine was 1200 mg/m2, with a recommended Phase II dose of 1000 mg/m2. Myelosuppression (leukopenia) was dose limiting; other commonly observed treatment toxicities were nausea/vomiting, mucositis, and hyperlacrimation. Although the 1200 mg/m2 dose was tolerated during the initial few cycles of therapy, chronic administration could not be maintained secondary to dose-limiting neutropenia. Since neutropenia was dose limiting, in a follow-up study, 10 patients received a modified regimen (treatment on days 1 and 6 instead of days 1 and 8) with the addition of granulocyte colony-stimulating factor (days 8-19). The addition of granulocyte colony-stimulating factor, however, did not permit further escalation of the iododeoxyuridine dose. Three partial responses and six minor responses were observed. Phase II studies of this regimen are ongoing in advanced colorectal and advanced pancreatic cancer to determine response rates in these diseases.
Collapse
Affiliation(s)
- J L Marshall
- Department of Medicine, Division of Hematology/Oncology, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
| | | | | |
Collapse
|
50
|
Henry DW, Marshall JL, Nazzaro D, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health Syst Pharm 1995; 52:2570-3. [PMID: 8590244 DOI: 10.1093/ajhp/52.22.2570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- D W Henry
- Department of Pharmacy, University of Kansas Medical Center (UKMC), Kansas City 66160-7330, USA
| | | | | | | | | |
Collapse
|